11,371 results on '"RESPIRATORY insufficiency"'
Search Results
2. A Narrative Review of Nutrition Therapy in Patients Receiving Extracorporeal Membrane Oxygenation
- Author
-
Terpsi Karpasiti
- Subjects
Adult ,medicine.medical_specialty ,Critical Illness ,medicine.medical_treatment ,Biomedical Engineering ,Biophysics ,MEDLINE ,Nutritional Status ,Bioengineering ,CINAHL ,law.invention ,Biomaterials ,Enteral Nutrition ,Extracorporeal Membrane Oxygenation ,Randomized controlled trial ,law ,medicine ,Extracorporeal membrane oxygenation ,Humans ,In patient ,Medical nutrition therapy ,Intensive care medicine ,business.industry ,General Medicine ,surgical procedures, operative ,Parenteral nutrition ,Observational study ,Respiratory Insufficiency ,business - Abstract
The use of extracorporeal membrane oxygenation (ECMO) in patients with severe cardiorespiratory failure has seen significant growth in the last decade. Despite this, there is paucity of data surrounding the optimum nutritional management for ECMO patients. This review aimed to describe current nutrition practices in patients receiving ECMO, critically appraise available studies and identify areas for future research. A literature search was conducted in PubMed, MEDLINE, and CINAHL Plus to identify all randomized trials and observational studies published between July 2000 and July 2020 investigating nutrition practices in critically ill adults receiving ECMO. The primary outcomes were nutritional adequacy, gastrointestinal complications, and physical function. Secondary outcomes included mortality, length of stay, and duration on ECMO support. From a total of 31 studies identified, 12 met the inclusion criteria. Nine observational studies were reviewed following eligibility assessment. Early enteral nutrition was deemed safe and feasible for ECMO patients; however, meeting nutritional targets was challenging. Utilizing alternative nutrition routes is an option, although risks and benefits should be taken into consideration. Data on gastrointestinal complications and other clinical outcomes were inconsistent, and no data were identified investigating the effects of nutrition on the physical and functional recovery of ECMO patients. Nutrition therapy in ECMO patients should be provided in line with current guidelines for nutrition in critical illness until further data are available. Further prospective, randomized studies investigating optimum nutrition practices and effects on clinical and functional outcomes are urgently required.
- Published
- 2022
3. Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab
- Author
-
Nuria Fernández-Hidalgo, Arnau Monforte-Pallarés, Fernando Salvador, Simeón Eremiev-Eremiev, Marta Miarons, Benito Almirante, Santiago Pérez-Hoyos, Júlia Sellarès-Nadal, Adrián Sánchez-Montalvá, Xavier Durà, Salvador Augustin, Júlia Sampol, Juan Espinosa-Pereiro, Alfredo Guillén-Del-Castillo, Abiu Sempere-González, Andrés Antón, and Pau Bosch-Nicolau
- Subjects
Adult ,Male ,ARDS ,medicine.medical_specialty ,COVID19 ,Viral pneumonia ,Lung injury ,Antibodies, Monoclonal, Humanized ,law.invention ,Cohort Studies ,chemistry.chemical_compound ,Tocilizumab ,law ,Internal medicine ,Inmunomodulación ,Clinical endpoint ,Humans ,Medicine ,Respiratory Distress Syndrome ,SARS-CoV-2 ,business.industry ,Hazard ratio ,COVID-19 ,General Medicine ,Middle Aged ,medicine.disease ,Intensive care unit ,IL6 ,COVID-19 Drug Treatment ,Neumonía viral ,Treatment Outcome ,chemistry ,Respiratory failure ,Original Article ,Female ,Immonomodulation ,Respiratory Insufficiency ,business ,Cohort study - Abstract
Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID-19). The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others.We report the preliminary results from the Vall d'Hebron cohort study at Vall d'Hebron University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed SARS-CoV-2 infection and who were treated with tocilizumab until March 25th.82 patients with COVID-19 received at least one dose of tocilizumab. The mean (± SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and the median (IQR) age-adjusted Charlson index at baseline was 3 (1-4) points. Respiratory failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median time from symptom onset to ARDS development was 8 (5-11) days. Mortality at 7 days was 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3-8.5 (age-adjusted hazard ratio for mortality 2.1; 95% CI, 0.8-5.8) if tocilizumab was administered after the onset of ARDS.Early administration of tocilizumab in patients needing oxygen supplementation may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data regarding the precise timing in of initiation of the treatment with tocilizumab.Los tratamientos inmunomoduladores para la prevención del daño pulmonar están siendo ampliamente estudiados contra la COVID-19. El objetivo primario es evaluar la mortalidad a los 7 días después de la administración de tocilizumab. El objetivo secundario es el ingreso en UCI, el desarrollo de distrés respiratorio agudo e insuficiencia respiratoria aguda entre otros.Informamos sobre los resultados preliminares de la cohorte del Hospital Universitario Vall d’Hebron en Barcelona (España), que incluye todos los pacientes consecutivos con infección confirmada por SARS-CoV-2 y que recibieron tratamiento con tocilizumab hasta el 25 de marzo 2020.Ochenta y dos pacientes con COVID-19 recibieron al menos una dosis de tocilizumab. La edad media (±DE) fue de 59,1 (±19,8) años, el 63% eran hombres, 22% correspondía a paciente nacidos fuera de España, y la mediana (RIC) del índice de Charlson ajustado por edad en el momento basal fue de 3 (1-4) puntos. Sesenta y dos pacientes (75,6%) y 45 pacientes (54,9%) desarrollaron insuficiencia respiratoria y distrés respiratorio agudo respectivamente. La mediana de tiempo desde el inicio de los síntomas hasta el desarrollo de ditrés fue de 8 días (5-11). La mortalidad a los 7 días fue del 26,8% La hazard ratio de mortalidad fue del 3,3; IC 95% 1,3-8,5 (la hazard ratio de mortalidad ajustada por edad fue de 2,1; IC 95% 0,8-5,8) si el tocilizumab se administraba después del inicio del distrés respiratorio.La administración precoz de tocilizumab en pacientes con suplementos de oxígeno podría ser crítica para la recuperación de los pacientes. Nuestros datos podrían ayudar a tomar decisiones clínicas hasta que se disponga de más información sobre el momento adecuado para iniciar el tratamiento con tocilizumab.
- Published
- 2022
4. Advance Identification of Patients With Chronic Conditions and Acute Respiratory Failure at Greatest Risk for High-Intensity, Costly Care
- Author
-
Lois Downey, Nita Khandelwal, Ruth A. Engelberg, J. Randall Curtis, and Peter M. May
- Subjects
Chronic condition ,medicine.medical_specialty ,Total cost ,medicine.medical_treatment ,Context (language use) ,Article ,law.invention ,law ,medicine ,Humans ,Acute respiratory failure ,General Nursing ,Aged ,Retrospective Studies ,Mechanical ventilation ,Respiratory Distress Syndrome ,business.industry ,High intensity ,Retrospective cohort study ,Respiration, Artificial ,Intensive care unit ,Intensive Care Units ,Anesthesiology and Pain Medicine ,Chronic Disease ,Emergency medicine ,Neurology (clinical) ,Respiratory Insufficiency ,business - Abstract
CONTEXT: Patients with underlying chronic illness requiring mechanical ventilation for acute respiratory failure are at risk for poor outcomes and high costs. OBJECTIVES: Identify characteristics at time of intensive care unit (ICU) admission that identify patients at highest risk for high-intensity, costly care. METHODS: Retrospective cohort study using electronic health and financial records (2011–2017) for patients requiring ≥48 hours of mechanical ventilation with ≥1 underlying chronic condition at an academic healthcare system. Main outcome was total cost of index hospitalization. Exposures of interest included number and type of chronic conditions. We used finite mixture models to identify the highest-cost group. RESULTS: 4,892 patients met study criteria. Median cost for index hospitalization was $135,238 (range, $9,748-$3,176,065). Finite mixture modelling identified three classes with mean costs of $89,980, $150,603, and $277,712. Patients more likely to be in the high-cost class were: 1) < 72 years old (OR: 2.03; 95% CI:1.63, 2.52); 2) with dementia (OR: 1.55; 95% CI:1.17, 2.06) or chronic renal failure (OR: 1.27; 95% CI:1.08, 1.48); 3) weight loss ≥ 5% in year prior to hospital admission (OR: 1.25; 95% CI:1.05, 1.48); and 4) hospitalized during prior year (OR: 1.92; 95% CI:1.58, 2.35). CONCLUSION: Among patients with underlying chronic illness and acute respiratory failure, we identified characteristics associated with the highest costs of care. Identifying these patients may be of interest to healthcare systems and hospitals and serve as one indication to invest resources in palliative and supportive care programs that ensure this care is consistent with patients’ goals.
- Published
- 2022
5. Association of Proximity to a Long-Term Acute Care Hospital With Hospital Tracheostomy Practices
- Author
-
Anuj B. Mehta, Daniel D. Matlock, and Ivor S. Douglas
- Subjects
Adult ,Male ,medicine.medical_specialty ,Future studies ,Sociodemographic Factors ,medicine.medical_treatment ,Psychological intervention ,Transportation ,Comorbidity ,Critical Care and Intensive Care Medicine ,California ,Article ,Tracheostomy ,Acute care ,medicine ,Hospital discharge ,Humans ,Hospital Mortality ,Aged ,Retrospective Studies ,Mechanical ventilation ,Aged, 80 and over ,business.industry ,Retrospective cohort study ,Odds ratio ,Middle Aged ,Long-Term Care ,Respiration, Artificial ,Hospitals ,Respiratory failure ,Emergency medicine ,Female ,business ,Respiratory Insufficiency - Abstract
OBJECTIVES Availability of long-term acute care hospitals has been associated with hospital discharge practices. It is unclear if long-term acute care hospital availability can influence patient care decisions. We sought to determine the association of long-term acute care hospital availability at different hospitals with the likelihood of tracheostomy. DESIGN Retrospective cohort study. SETTING California Patient Discharge Database, 2016-2018. PATIENTS Adult patients receiving mechanical ventilation for respiratory failure. INTERVENTIONS None. MEASUREMENTS AND MAIN RESULTS Using the California Patient Discharge Database 2016-2018, we identified all mechanically ventilated patients and those who received tracheostomy. We determine the association between tracheostomy and the distance between each hospital and the nearest long-term acute care hospital and the number of long-term acute care hospital beds within 20 miles of each hospital. Among 281,502 hospitalizations where a patient received mechanical ventilation, 22,899 (8.1%) received a tracheostomy. Patients admitted to a hospital closer to a long-term acute care hospital compared with those furthest from a long-term acute care hospital had 38.9% (95% CI, 33.3-44.6%) higher odds of tracheostomy (closest hospitals 8.7% vs furthest hospitals 6.3%, adjusted odds ratio = 1.65; 95% CI, 1.40-1.95). Patients had a 32.4% (95% CI, 27.6-37.3%) higher risk of tracheostomy when admitted to a hospital with more long-term acute care hospital beds in the immediate vicinity (most long-term acute care hospital beds within 20 miles 8.9% vs fewest long-term acute care hospital beds 6.7%, adjusted odds ratio = 1.54; 95% CI, 1.31-1.80). Distance to the nearest long-term acute care hospital was inversely correlated with hospital risk-adjusted tracheostomy rates (ρ = -0.25; p < 0.0001). The number of long-term acute care hospital beds within 20 miles was positively correlated with hospital risk-adjusted tracheostomy rates (ρ = 0.22; p < 0.0001). CONCLUSIONS Proximity and availability of long-term acute care hospital beds were associated with patient odds of tracheostomy and hospital tracheostomy practices. These findings suggest a hospital effect on tracheostomy decision-making over and above patient case-mix. Future studies focusing on shared decision-making for tracheostomy are needed to ensure goal-concordant care for prolonged mechanical ventilation.
- Published
- 2023
6. Changes in oxygenation and clinical outcomes with awake prone positioning in patients with suspected COVID-19 In Low-Resource settings: A retrospective cohort study
- Author
-
Leydis Lora, Dairo Rodelo, Carmelo Dueñas-Castell, Wilfrido Coronell, Amilkar Almanza, Diana Borre-Naranjo, and Jose Rojas-Suarez
- Subjects
Adult ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,medicine.medical_treatment ,Disease ,Respiratory failure ,Critical Care and Intensive Care Medicine ,Oxygen therapy ,Prone Position ,Medicine ,Humans ,In patient ,Wakefulness ,Mortality ,Aged ,Retrospective Studies ,business.industry ,SARS-CoV-2 ,Awake prone position ,COVID-19 ,Retrospective cohort study ,Oxygenation ,Middle Aged ,Resources ,Prone position ,Emergency medicine ,business ,Respiratory Insufficiency - Abstract
Introduction This study aimed to describe the use of awake prone positioning (APP) and conventional oxygen therapy (COT) in patients with suspected coronavirus disease (COVID-19) and respiratory failure in a limited-resource setting. Methods This was a retrospective cohort study of hospitalized patients aged ≥18 years old who were placed in an awake prone position due to hypoxemic respiratory failure and suspected COVID-19. The patients were selected from a tertiary center in Cartagena, Colombia, between March 1, 2020, and August 31, 2020. Demographic, clinical, and laboratory variables were collated, and all the variables were compared between the groups. Results The median age of the participants was 63 (IQR, 48.8-73) years (survivors: 59 [IQR, 43.568] years vs. non-survivors: 70 [IQR, 63-78] years, P ≤ .001). Of the 1470 patients admitted for respiratory symptoms, 732 (49.8%) were hospitalized for more than 24 h, and 212 patients developed respiratory failure and required COT and APP (overall hospital mortality, 34% [73/212]). The mean rank difference in PaO2/FiO2 before and after APP was higher in the survivors than in the non-survivors (201.1-252.6, mean rank difference = 51.5, P = .001 vs. 134.1-172.4, mean rank difference = 38.28, P = .24, respectively). Conclusion While using COT in conjunction with APP can improve respiratory failure in patients with suspected COVID-19 in low-resource settings, persistent hypoxemia after APP can identify patients with higher mortality risk. More evidence is needed to establish the role of this strategy.
- Published
- 2023
7. Perioperative Noninvasive Ventilation After Adult or Pediatric Surgery: A Comprehensive Review
- Author
-
Artem Kuzovlev, Giovanni Landoni, Luca Cabrini, Valery Likhvantsev, Landoni, G., Likhvantsev, V., Kuzovlev, A., and Cabrini, L.
- Subjects
Adult ,medicine.medical_specialty ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,surgery ,03 medical and health sciences ,0302 clinical medicine ,030202 anesthesiology ,Pediatric surgery ,medicine ,postoperative ,Humans ,Intubation ,Respiratory function ,perioperative ,Child ,Hypoxia ,acute respiratory failure ,noninvasive ventilation ,postoperative pulmonary complication ,Noninvasive Ventilation ,business.industry ,Perioperative ,Respiration, Artificial ,Obesity, Morbid ,Cardiac surgery ,Anesthesiology and Pain Medicine ,Cardiothoracic surgery ,Anesthesia ,Noninvasive ventilation ,Respiratory Insufficiency ,Cardiology and Cardiovascular Medicine ,business ,Abdominal surgery - Abstract
Postoperative pulmonary complications and acute respiratory failure are among the leading causes of adverse postoperative outcomes. Noninvasive ventilation may safely and effectively prevent acute respiratory failure in high-risk patients after cardiothoracic surgery and after abdominal surgery. Moreover, noninvasive ventilation can be used to treat postoperative hypoxemia, particularly after abdominal surgery. Noninvasive ventilation also can be helpful to prevent or manage intraoperative acute respiratory failure during non-general anesthesia, primarily in patients with poor respiratory function. Finally, noninvasive ventilation is superior to standard preoxygenation in delaying desaturation during intubation in morbidly obese and in critically ill hypoxemic patients. The few available studies in children suggest that noninvasive ventilation could be safe and valuable in treating hypoxemic or hypercapnic acute respiratory failure after cardiac surgery; on the other hand, it could be dangerous after tracheoesophageal correction.
- Published
- 2022
8. Development and Validation of a Risk Score for Respiratory Failure After Cardiac Surgery
- Author
-
Asma Zainab, Edward A. Graviss, Sahar Fatima, Faisal Masud, Duc T. Nguyen, and Thomas E. MacGillivray
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Risk Assessment ,law.invention ,Postoperative Complications ,law ,Cardiopulmonary bypass ,Humans ,Medicine ,Cardiac Surgical Procedures ,Aged ,Retrospective Studies ,Framingham Risk Score ,business.industry ,Incidence ,Cardiogenic shock ,Middle Aged ,Prognosis ,medicine.disease ,Texas ,Intensive care unit ,Cardiac surgery ,Intensive Care Units ,Respiratory failure ,Cardiovascular Diseases ,Emergency medicine ,Female ,Surgery ,Respiratory Insufficiency ,Cardiology and Cardiovascular Medicine ,business ,Complication ,Body mass index ,Follow-Up Studies - Abstract
Background Postoperative respiratory failure, defined as ventilator dependency for more than 48 hours or unplanned reintubation within 30 days, is a costly complication of cardiac surgery that increases mortality and length of stay. Stratification of patients by risk upon intensive care unit admission could identify cases requiring early measures to prevent respiratory failure. This study aimed to develop and validate a risk score for postoperative respiratory failure after cardiac surgery. Methods This retrospective analysis of 4262 patients admitted to the cardiovascular intensive care unit after major cardiac surgery between January 2013 and December 2017, used The Society of Thoracic Surgeons database and ventilator data from the respiratory therapy department. Patients were randomly and equally assigned to development and validation cohorts. Covariates used in the multivariable models were assigned weighted points proportional to their β regression coefficient values to create the risk score, which categorized patients into low, medium, and high risk of postoperative respiratory failure. Results In both cohorts, postoperative respiratory failure risk was significantly different between risk categories. Compared with low-risk patients, moderate-risk patients had a 2 times greater risk, and high-risk patients had a 4-7 times greater risk. Body mass index, previous cardiac surgery, cardiopulmonary bypass, cardiogenic shock, pulmonary disease presence, baseline functional status, hemodynamic instability, and number of blood products used intraoperatively were significant predictors of respiratory failure. Conclusions This risk score can stratify patients by risk for developing postoperative respiratory failure after major cardiac surgery, which may help in the development of preventive measures.
- Published
- 2022
9. Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research
- Author
-
James Glenister, Sampath Weerakkody, Giacomo Boscaini-Gilroy, Pietro Arina, Hugh Montgomery, Sam Cotterell, and Mervyn Singer
- Subjects
Pulmonary and Respiratory Medicine ,Mechanical ventilation ,Personal View ,medicine.medical_specialty ,Noninvasive Ventilation ,SARS-CoV-2 ,business.industry ,medicine.medical_treatment ,COVID-19 ,medicine.disease ,Respiration, Artificial ,Corrections ,Pneumonia ,Breathing ,medicine ,Humans ,Intubation ,Observational study ,Prospective Studies ,Continuous positive airway pressure ,Respiratory Insufficiency ,Complication ,business ,Airway ,Intensive care medicine - Abstract
Non-invasive respiratory support (NIRS) has increasingly been used in the management of COVID-19-associated acute respiratory failure, but questions remain about the utility, safety, and outcome benefit of NIRS strategies. We identified two randomised controlled trials and 83 observational studies, compromising 13 931 patients, that examined the effects of NIRS modalities-high-flow nasal oxygen, continuous positive airway pressure, and bilevel positive airway pressure-on patients with COVID-19. Of 5120 patients who were candidates for full treatment escalation, 1880 (37%) progressed to invasive mechanical ventilation and 3658 of 4669 (78%) survived to study end. Survival was 30% among the 1050 patients for whom NIRS was the stated ceiling of treatment. The two randomised controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation. Reported complication rates were low. Overall, the studies indicate that NIRS in patients with COVID-19 is safe, improves resource utilisation, and might be associated with better outcomes. To guide clinical decision making, prospective, randomised studies are needed to address timing of intervention, optimal use of NIRS modalities-alone or in combination-and validation of tools such as oxygenation indices, response to a trial of NIRS, and inflammatory markers as predictors of treatment success.
- Published
- 2022
10. Clinical impact of pneumothorax in patients with Pneumocystis jirovecii pneumonia and respiratory failure in an HIV-negative cohort
- Author
-
Sang Hoon Lee, Seung Hyun Yong, Ji Ye Jung, Song Yee Kim, Kyung Soo Chung, Young Ae Kang, Ji Soo Choi, Young Sam Kim, Se Hyun Kwak, Su Hwan Lee, Eun-Young Kim, Ah Young Leem, Min Chul Kim, Byung Hoon Park, Eun Hye Lee, Sung Ryeol Kim, Moo Suk Park, and Chang Hwan Seol
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Pneumocystis carinii ,Cohort Studies ,Diseases of the respiratory system ,Internal medicine ,Republic of Korea ,Medicine ,Humans ,In patient ,Aged ,Retrospective Studies ,RC705-779 ,business.industry ,Pneumocystis ,Pneumonia, Pneumocystis ,Research ,Pneumocystis jirovecii Pneumonia ,Pneumothorax ,Pneumonia ,Middle Aged ,respiratory system ,medicine.disease ,Prognosis ,Respiration, Artificial ,respiratory tract diseases ,Intensive Care Units ,surgical procedures, operative ,Respiratory failure ,Risk factors ,Cohort ,Female ,business ,Respiratory insufficiency - Abstract
Background Pneumocystis jirovecii pneumonia (PCP) with acute respiratory failure can result in development of pneumothorax during treatment. This study aimed to identify the incidence and related factors of pneumothorax in patients with PCP and acute respiratory failure and to analyze their prognosis. Methods We retrospectively reviewed the occurrence of pneumothorax, including clinical characteristics and results of other examinations, in 119 non-human immunodeficiency virus patients with PCP and respiratory failure requiring mechanical ventilator treatment in a medical intensive care unit (ICU) at a tertiary-care center between July 2016 and April 2019. Results During follow up duration, twenty-two patients (18.5%) developed pneumothorax during ventilator treatment, with 45 (37.8%) eventually requiring a tracheostomy due to weaning failure. Cytomegalovirus co-infection (odds ratio 13.9; p = 0.013) was related with occurrence of pneumothorax in multivariate analysis. And development of pneumothorax was not associated with need for tracheostomy and mortality. Furthermore, analysis of survivor after 28 days in ICU, patients without pneumothorax were significantly more successful in weaning from mechanical ventilator than the patients with pneumothorax (44% vs. 13.3%, p = 0.037). PCP patients without pneumothorax showed successful home discharges compared to those who without pneumothorax (p = 0.010). Conclusions The development of pneumothorax increased in PCP patient with cytomegalovirus co-infection, pneumothorax might have difficulty in and prolonged weaning from mechanical ventilators, which clinicians should be aware of when planning treatment for such patients.
- Published
- 2022
11. Management of Respiratory Distress and Failure in Morbidly and Super Obese Patients During Critical Care Transport
- Author
-
Michael J. Lauria, Darren Braude, Christopher W. Root, and Adam L. Gottula
- Subjects
Mechanical ventilation ,Respiratory Distress Syndrome ,medicine.medical_specialty ,education.field_of_study ,Noninvasive Ventilation ,Modalities ,Critical Care ,Respiratory distress ,business.industry ,medicine.medical_treatment ,Standard treatment ,Population ,Respiratory physiology ,Emergency Nursing ,Respiration, Artificial ,Emergency Medicine ,Humans ,Medicine ,Intubation ,Obesity ,Respiratory system ,Respiratory Insufficiency ,business ,Intensive care medicine ,education - Abstract
Morbidly and super obese patients are a unique patient population that presents critical care transport providers with unique clinical and logistical challenges in the setting of respiratory distress and failure. These patients are more likely to have chronic respiratory issues at baseline, unique anatomic and physiologic abnormalities, and other comorbidities that leave them poorly able to tolerate respiratory illness or injury. This requires specialized understanding of their respiratory mechanics as well as how to tailor standard treatment modalities, such as noninvasive ventilation, to meet their needs. Also, careful and deliberate planning is required to address the specific anatomic and physiologic characteristics of this population if intubation and mechanical ventilation are needed. Finally, their dimensions and weight also have distinct consequences on transport vehicle considerations. This article reviews the pathophysiology, management, and critical care transport considerations for this unique patient population in respiratory distress and failure.
- Published
- 2022
12. Diaphragmatic dysfunction in neuromuscular disease, an MRI study
- Author
-
Pieter A. van Doorn, Wim G. M. Janssen, Ans T. van der Ploeg, Marleen de Bruijne, Remco G. M. Timmermans, Harm A.W.M. Tiddens, Nadine A. M. E. van der Beek, Gijs van Tulder, Pierluigi Ciet, L. Harlaar, Esther Brusse, Neurology, Pediatrics, Radiology & Nuclear Medicine, and Rehabilitation Medicine
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neuromuscular disease ,Diaphragm ,Diaphragmatic breathing ,Disease ,Internal medicine ,Medicine ,Humans ,Diaphragmatic weakness ,Anterior posterior ,Genetics (clinical) ,Aged ,business.industry ,Glycogen Storage Disease Type II ,Neuromuscular Diseases ,Motor neuron ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Diaphragm (structural system) ,medicine.anatomical_structure ,Cross-Sectional Studies ,Neurology ,Spirometry ,Case-Control Studies ,Pediatrics, Perinatology and Child Health ,Cardiology ,Female ,Neurology (clinical) ,business ,Respiratory Insufficiency ,Thoracic wall - Abstract
The aim of this exploratory study was to evaluate diaphragmatic function across various neuromuscular diseases using spirometry-controlled MRI. We measured motion of the diaphragm relative to that of the thoracic wall (cranial-caudal ratio vs. anterior posterior ratio; CC-AP ratio), and changes in the diaphragmatic curvature (diaphragm height and area ratio) during inspiration in 12 adults with a neuromuscular disease having signs of respiratory muscle weakness, 18 healthy controls, and 35 adult Pompe patients – a group with prominent diaphragmatic weakness. CC-AP ratio was lower in patients with myopathies (n=7, 1.25±0.30) and motor neuron diseases (n=5, 1.30±0.10) than in healthy controls (1.37±0.14; p=0.001 and p=0.008), but not as abnormal as in Pompe patients (1.12±0.18; p=0.011 and p=0.024). The mean diaphragm height ratio was 1.17±0.33 in patients with myopathies, pointing at an insufficient diaphragmatic contraction. This was also seen in patients with Pompe disease (1.28±0.36), but not in healthy controls (0.82±0.33) or patients with motor neuron disease (0.82±0.24). We conclude that spirometry-controlled MRI enables us to investigate respiratory dysfunction across neuromuscular diseases, suggesting that the diaphragm is affected in a different way in myopathies and motor neuron diseases. Whether MRI can also be used to evaluate progression of diaphragmatic dysfunction requires additional studies.
- Published
- 2022
13. COVID-19 Pneumonia and ROX index: Time to set a new threshold for patients admitted outside the ICU
- Author
-
Gustavo Olaizola, Mauro Castro Sayat, Nicolás Colaianni, Greta Spoladore, Stefano Nava, Irene Prediletto, Roberto Dongilli, Maria Laura Vega, Lara Pisani, Micaela Romagnoli, Guillermo Montiel, Vega M.L., Dongilli R., Olaizola G., Colaianni N., Sayat M.C., Pisani L., Romagnoli M., Spoladore G., Prediletto I., Montiel G., and Nava S.
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Respiratory rate ,medicine.medical_treatment ,Brief Communication ,medicine.disease_cause ,HFNC ,law.invention ,Diseases of the respiratory system ,03 medical and health sciences ,ROX index ,0302 clinical medicine ,Respiratory Rate ,AHRF ,law ,Fraction of inspired oxygen ,Non invasive respiratory support ,Intubation, Intratracheal ,medicine ,Humans ,Intubation ,Oximetry ,030212 general & internal medicine ,Acute hypoxemic respiratory failure ,Survival analysis ,Retrospective Studies ,Mechanical ventilation ,Noninvasive Ventilation ,RC705-779 ,medicine.diagnostic_test ,SARS-CoV-2 ,business.industry ,Oxygen Inhalation Therapy ,COVID-19 ,Intensive care unit ,High flow nasal cannula ,Intensive Care Units ,Pulse oximetry ,030228 respiratory system ,Emergency medicine ,Respiratory Insufficiency ,business ,Nasal cannula - Abstract
High flow nasal cannula (HFNC) is used to treat acute hypoxemic respiratory failure (AHRF) even outside the ICU and the ROX index (pulse oximetry/fraction of inspired oxygen/respiratory rate) may predict HFNC failure. OBJECTIVE: The purpose of this investigation was therefore to verify whether the ROX index is an accurate predictor of HFNC failure for COVID-19 patients treated outside the intensive care unit (ICU) and to evaluate the validity of the previously suggested threshold. DESIGN: Multicenter study. Retrospective observational analysis of prospectively collected data. SETTING: 3 centres specialized in non-invasive respiratory support (Buenos Aires, Argentina; Bolzano and Treviso, Italy). Patients treated outside the ICU were analysed MEASUREMENTS: The variables to calculate the ROX index were collected during the first day of therapy at 2, 6, 12 and 24 hours and then recorded every 24 hours. HFNC failure was defined as escalation of respiratory support to invasive mechanical ventilation (IMV) or death. MAIN RESULTS: A total of 35 (29%) patients failed HFNC and required intubation. ROC analysis identified the 12-hour ROX index as the best predictor of intubation with an AUC of 0.7916[CI 95% 0.6905-0.8927] and the best threshold to be 5.99[Specificity 96% Sensitivity 62%]. In the survival analysis, a ROX value
- Published
- 2022
14. Atypical Antipsychotic Safety in the CICU
- Author
-
Amrish Deshmukh, Scott W. Ketcham, Hallie C. Prescott, Sarah Adie, Michael P. Thomas, Matthew C. Konerman, Ahmad A. Abdul-Aziz, Keerthi Gondi, and Matthew P. Hanna
- Subjects
Male ,Olanzapine ,medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Shock, Cardiogenic ,Atypical antipsychotic ,Ventricular tachycardia ,Quetiapine Fumarate ,Internal medicine ,Intensive care ,Humans ,Medicine ,cardiovascular diseases ,Antipsychotic ,Adverse effect ,Aged ,Retrospective Studies ,Aged, 80 and over ,Heart Failure ,Endocarditis ,business.industry ,Coronary Care Units ,Delirium ,Arrhythmias, Cardiac ,Length of Stay ,Middle Aged ,medicine.disease ,Heart Arrest ,Long QT Syndrome ,Emergency medicine ,Tachycardia, Ventricular ,cardiovascular system ,Cardiology ,ST Elevation Myocardial Infarction ,Quetiapine ,Female ,Hypotension ,medicine.symptom ,Respiratory Insufficiency ,Cardiology and Cardiovascular Medicine ,business ,Antipsychotic Agents ,medicine.drug - Abstract
Atypical antipsychotics are used in cardiac intensive care units (CICU) to treat delirium despite limited data on safety in patients with acute cardiovascular conditions. Patients treated with these agents may be at higher risk for adverse events such as QTc prolongation and arrhythmias. We performed a retrospective cohort study of 144 adult patients who were not receiving antipsychotics before admission and received olanzapine (n = 50) or quetiapine (n = 94) in the Michigan Medicine CICU. Data on baseline characteristics, antipsychotic dose and duration, length of stay, and adverse events were collected. Adverse events included ventricular tachycardia (sustained ventricular tachycardia attributed to the medication), hypotension (systolic blood pressure90 mm Hg attributed to the medication), and QTc prolongation (QTc increase by ≥60 ms or to an interval ≥500 ms). Twenty-six patients (18%) experienced an adverse event. Of those adverse events, 20 patients (14%) experienced QTc prolongation, 3 patients (2%) had ventricular tachycardia, and 3 patients (2%) had hypotension. Patients who received quetiapine had a higher rate of adverse events (25% vs 6%, p = 0.01) including QTc prolongation (18% vs 6%, p = 0.046). Intensive care unit length of stay was shorter in patients who received olanzapine (6.5 vs 9.5 days, p = 0.047). Eighteen patients (13%) had their antipsychotic continued at discharge from the hospital. In conclusion, QTc prolongation was more common in patients treated with quetiapine versus olanzapine although the number of events was relatively low with both agents in a CICU cohort.
- Published
- 2022
15. Posttransplant Pneumonia Among Solid Organ Transplant Recipients Followed in Intensive Care Unit
- Author
-
Mehmet Haberal, Helin Sahinturk, Pinar Zeyneloglu, Çağla Yazar, and Fatma İrem Yeşiler
- Subjects
Adult ,Male ,medicine.medical_specialty ,Poor prognosis ,law.invention ,Risk Factors ,law ,Internal medicine ,medicine ,Humans ,Respiratory system ,Retrospective Studies ,Transplantation ,business.industry ,Mortality rate ,Pneumonia ,Middle Aged ,medicine.disease ,Kidney Transplantation ,Intensive care unit ,Transplant Recipients ,Intensive Care Units ,Treatment Outcome ,Health evaluation ,Cohort ,Female ,Respiratory Insufficiency ,Solid organ transplantation ,business - Abstract
OBJECTIVES Pneumonia is a significant cause of morbidity and mortality in solid-organ transplant recipients. We studied the demographic characteristics, respiratory management, and outcomes of solid-organ transplant recipients with pneumonia in an intensive care unit. MATERIALS AND METHODS There have been 2857 kidney, 687 liver, and 142 heart transplants performed between October 16, 1985, and February 28, 2021, at our center. We retrospectively analyzed records for 51 of 193 recipients with pneumonia during the posttransplant period between January 1, 2016, and December 31, 2018. RESULTS Fifty-one of 193 recipients were followed in the intensive care unit. Mean age was 45.4 ± 16.6 years among 42 male (82.4%) and 9 female (17.6%) recipients. Twenty-six patients (51%) underwent kidney transplant, 14 (27.5%) liver transplant, 7 (13.7%) heart transplant, and 4 (7.8%) combined kidney and liver transplant. Most pneumonia episodes occurred 6 months after transplant (70.6%) with acute hypoxemic respiratory failure. Mean Acute Physiology and Chronic Health Evaluation System II score was 18.9 ± 7.7, and the Sequential Organ Failure Assessment score was 8.5 ± 3.9 at intensive care unit admission. Whereas 66.7% of pneumonia cases were nosocomial acquired, 33.3% were community acquired. The intensive care unit and 28-day mortality rates were 39.2% and 64.7%, respectively. CONCLUSIONS Solid-organ transplant recipients with pneumonia have been associated with poor prognosis. Our cohort followed in the intensive care unit comprised mostly patients with nosocomial pneumonia with acute hypoxemic respiratory failure, hospitalized 6 months after transplant with high Acute Physiology and Chronic Health Evaluation System II scores predictive of mortality. In this high-risk patient group, careful follow-up, early discovery of warning signs, and rapid treatment initiation could improve the outcomes in the intensive care unit.
- Published
- 2022
16. COVID-19 associated myocarditis: A systematic review
- Author
-
Kaushal Shah, William Haussner, Jonathan Kamler, Danielle Haussner, Antonio P. DeRosa, Jane Torres-Lavoro, and Jacqueline Tran
- Subjects
medicine.medical_specialty ,Viral Myocarditis ,Myocarditis ,Primary cardiac collapse ,Cardiomyopathy ,Heart failure ,Article ,Risk Factors ,Internal medicine ,medicine ,Humans ,biology ,business.industry ,COVID-19 ,General Medicine ,medicine.disease ,Troponin ,Dyspnea ,Respiratory failure ,Shock (circulatory) ,Systematic review ,Emergency Medicine ,Cardiology ,biology.protein ,Etiology ,Takotsubo cardiomyopathy ,medicine.symptom ,Respiratory Insufficiency ,business - Abstract
Background Most COVID-19 infections result in a viral syndrome characterized by fever, cough, shortness of breath, and myalgias. A small but significant proportion of patients develop severe COVID-19 resulting in respiratory failure. Many of these patients also develop multi-organ dysfunction as a byproduct of their critical illness. Although heart failure can be a part of this, there also appears to be a subset of patients who have primary cardiac collapse from COVID-19. Objective Conduct a systematic review of COVID-19-associated myocarditis, including clinical presentation, risk factors, and prognosis. Discussion Our review demonstrates two distinct etiologies of primary acute heart failure in surprisingly equal incidence in patients with COVID-19: viral myocarditis and Takotsubo cardiomyopathy. COVID myocarditis, Takotsubo cardiomyopathy, and severe COVID-19 can be clinically indistinguishable. All can present with dyspnea and evidence of cardiac injury, although in myocarditis and Takotsubo this is due to primary cardiac dysfunction as compared to respiratory failure in severe COVID-19. Conclusion COVID-19-associated myocarditis differs from COVID-19 respiratory failure by an early shock state. However, not all heart failure from COVID-19 is from direct viral infection; some patient's develop takotsubo cardiomyopathy. Regardless of etiology, steroids may be a beneficial treatment, similar to other critically ill COVID-19 patients. Evidence of cardiac injury in the form of ECG changes or elevated troponin in patients with COVID-19 should prompt providers to consider concurrent myocarditis.
- Published
- 2022
17. Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non–small-Cell Lung Cancer Involvement in the ICU
- Author
-
Damien Contou, Frédéric Gonzalez, Anne-Sophie Moreau, M. Pineton de Chambrun, E. De Montmollin, Romain Persichini, Florent Wallet, Anne Oppenheimer, Aude Gibelin, N. Dufour, Jean-Damien Ricard, Stéphane Gaudry, Julien Mayaux, P. Jaubert, Y. Akrour, Annabelle Stoclin, Alexandre Lautrette, Y. Tandjaoui-Lambiotte, B. Duchemann, F. El Kouari, and Khalil Chaïbi
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,MEDLINE ,Adenocarcinoma of Lung ,Critical Care and Intensive Care Medicine ,law.invention ,Erlotinib Hydrochloride ,Crizotinib ,law ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Humans ,Medicine ,Acute respiratory failure ,Lung cancer ,Protein Kinase Inhibitors ,Aged ,Neoplasm Staging ,Retrospective Studies ,Acrylamides ,Aniline Compounds ,Noninvasive Ventilation ,business.industry ,Oxygen Inhalation Therapy ,Gefitinib ,Middle Aged ,medicine.disease ,Respiration, Artificial ,Intensive care unit ,ErbB Receptors ,Survival Rate ,Intensive Care Units ,Female ,Non small cell ,Respiratory Insufficiency ,Cardiology and Cardiovascular Medicine ,business ,Tyrosine kinase - Published
- 2022
18. Early Tracheostomy for Managing ICU Capacity During the COVID-19 Outbreak
- Author
-
O Plans, R Padilla, Juan Carlos Figueira, A Lesmes, Santiago Pérez-Hoyos, J Prada, R. Ortiz, Andrea Castellví, Juan Carlos Montejo, B Castiñeiras, C Rodriguez-Solis, Rafael Cuena, A Santos-Peral, Laura Colinas, Oriol Roca, C Diaz, C De Haro, R Corrales, Jose L. Jimenez, F. Gordo, M M Cruz-Delgado, Concepción Vaquero, M C Martinez, A Gomez-Carranza, R. de Pablo, Fernando Frutos-Vivar, J Marin-Corral, A Naharro, Gemma Rialp, J A Sanchez-Giralt, A Ortega, Oscar Peñuelas, Joan R. Masclans, A Canabal, G. Hernández, José M. Añón, and F. Ramos
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,Pneumonia, Viral ,tracheostomy ,VFD, ventilator-free day ,resource ,Critical Care and Intensive Care Medicine ,law.invention ,Interquartile range ,law ,timing ,medicine ,Humans ,Intubation ,Propensity Score ,Pandemics ,IQR, interquartile range ,Aged ,Bed Occupancy ,Retrospective Studies ,Mechanical ventilation ,business.industry ,capacity ,COVID-19 ,Outbreak ,Retrospective cohort study ,Length of Stay ,Middle Aged ,failure-free ,medicine.disease ,Respiration, Artificial ,Intensive care unit ,BFD, bed-free day ,Intensive Care Units ,Pneumonia ,Spain ,Critical Care: Original Research ,Emergency medicine ,Female ,Respiratory Insufficiency ,Cardiology and Cardiovascular Medicine ,business ,LOS, length of stay - Abstract
Background During the first wave of the COVID-19 pandemic, shortages of ventilators and ICU beds overwhelmed health-care systems. Whether early tracheostomy reduces the duration of mechanical ventilation and ICU stay is controversial. Research Question Can failure-free day outcomes focused on ICU resources help to decide the optimal timing of tracheostomy in overburdened health-care systems during viral epidemics? Study Design and Methods This retrospective cohort study included consecutive patients with COVID-19 pneumonia who had undergone tracheostomy in 15 Spanish ICUs during the surge, when ICU occupancy modified clinician criteria to perform tracheostomy in Patients with COVID-19. We compared ventilator-free days at 28 and 60 days and ICU- and hospital bed-free days at 28 and 60 days in propensity score-matched cohorts who underwent tracheostomy at different timings (≤ 7 days, 8-10 days, and 11-14 days after intubation). Results Of 1,939 patients admitted with COVID-19 pneumonia, 682 (35.2%) underwent tracheostomy, 382 (56%) within 14 days. Earlier tracheostomy was associated with more ventilator-free days at 28 days (≤ 7 days vs > 7 days [116 patients included in the analysis]: median, 9 days [interquartile range (IQR), 0-15 days] vs 3 days [IQR, 0-7 days]; difference between groups, 4.5 days; 95% CI, 2.3-6.7 days; 8-10 days vs > 10 days [222 patients analyzed]: 6 days [IQR, 0-10 days] vs 0 days [IQR, 0-6 days]; difference, 3.1 days; 95% CI, 1.7-4.5 days; 11-14 days vs > 14 days [318 patients analyzed]: 4 days [IQR, 0-9 days] vs 0 days [IQR, 0-2 days]; difference, 3 days; 95% CI, 2.1-3.9 days). Except hospital bed-free days at 28 days, all other end points were better with early tracheostomy. Interpretation Optimal timing of tracheostomy may improve patient outcomes and may alleviate ICU capacity strain during the COVID-19 pandemic without increasing mortality. Tracheostomy within the first work on a ventilator in particular may improve ICU availability.
- Published
- 2022
19. Acute liver injury in the course of COVID-19
- Author
-
Katarzyna Szewczyk, Anna Grzywa-Celińska, Justyna Emeryk-Maksymiuk, Adam Krusiński, Janusz Milanowski, and Rafał Celiński
- Subjects
Acute liver injury ,medicine.medical_specialty ,COPD ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,Public Health, Environmental and Occupational Health ,COVID-19 ,medicine.disease ,Liver ,Internal medicine ,medicine ,Humans ,RNA, Viral ,Female ,Respiratory Insufficiency ,business ,Waste Management and Disposal ,Ecology, Evolution, Behavior and Systematics - Abstract
Although coronavirus disease 19 (COVID-19) most often affects the respiratory system, in the course of this disease, dysfunction of many other organs may also develop. The case is presented of a female patient, treated for a long time due to chronic obstructive pulmonary disease, complicated by chronic complete respiratory failure, and who was undergoing non-invasive mechanical ventilation at home. She was admitted to the Pneumonology Department due to exacerbation of the symptoms of her underlying disease. Several tests for SARS-CoV2 infection gave a negative result. During the patient's stay in the clinic, a rapid increase was observed in symptoms of respiratory failure, heart failure, and laboratory signs of acute liver damage. The next PCR test result proved to be positive. In addition to the case report, the possible impact of SARS-CoV2 infection on liver damage is also also discussed, along with a literature review on this topic.
- Published
- 2021
20. Noninvasive ventilation in patients with COVID-19 from the perspective of the risk of contamination: a narrative review
- Author
-
Adriana S. Garcia de Araújo, Lia Mara Wibelinger, Rebeca Nunes Silva, Guilherme Dionir Back, Snehil Dixit, Ross Arena, Cássia da Luz Goulart, Murilo Rezende Oliveira, Audrey Borghi-Silva, and Vanessa de Mello Konzen
- Subjects
Pulmonary and Respiratory Medicine ,Respiratory Distress Syndrome ,medicine.medical_specialty ,Noninvasive Ventilation ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,Public Health, Environmental and Occupational Health ,COVID-19 ,Context (language use) ,Contamination ,Respiration, Artificial ,Health team ,SAFER ,medicine ,Humans ,Immunology and Allergy ,Narrative review ,Acute respiratory failure ,In patient ,Respiratory Insufficiency ,Intensive care medicine ,business - Abstract
Introduction Non-invasive ventilation (NIV) can be a useful resource to treat acute respiratory failure (ARF), which occurs in patients with COVID-19. However, it is important to consider that there are still no clinical studies that have verified the safety of its use in increase of contamination. Areas covered Given the potential benefits and simultaneous concerns over the use of NIV in patients with COVID-19, further inquiry is necessary to reach a clinical consensus and provide recommendations for safe use, avoiding contamination. In this context, this narrative review, which included articles published in the Embase, SciELO, PEDro, Pubmed and Cochrane up to August 2021, is focused to evaluate available studies related to interfaces, types of circuits, recommended filters, cares for the environment and protective factors for NIV use in patients with COVID-19. Expert opinion The studies analyzed recommend that the use of NIV can be safe: 1) with equipment that allows the use of the helmet as a safer interface; 2) with double circuit and antimicrobial filter in the expiratory branch; 3) in an environment that allows negative pressure, reducing the dispersion of aerosol particles in the environment; 4) the health team must use the recommended PPE to avoid contamination.
- Published
- 2021
21. Inflammatory Myopathy Associated with Anti-mitochondrial Antibody Presenting Only with Respiratory Failure
- Author
-
Masaaki Matsushima, Katsuki Eguchi, Shintaro Fujii, Azusa Nagai, Ikuko Iwata, Yuki Oshima, Ichiro Yabe, and Kazuhiro Horiuchi
- Subjects
Pathology ,medicine.medical_specialty ,inflammatory myopathy ,medicine.medical_treatment ,immune-mediated necrotizing myopathy ,Case Report ,030204 cardiovascular system & hematology ,Inflammatory myopathy ,03 medical and health sciences ,0302 clinical medicine ,parasitic diseases ,Internal Medicine ,Humans ,Medicine ,Type II respiratory failure ,Muscle, Skeletal ,Autoantibodies ,Myositis ,biology ,business.industry ,anti-mitochondrial antibodies ,Muscle weakness ,General Medicine ,Immunotherapy ,Middle Aged ,medicine.disease ,Respiratory failure ,biology.protein ,Female ,030211 gastroenterology & hepatology ,immunotherapy ,medicine.symptom ,Antibody ,Differential diagnosis ,Respiratory Insufficiency ,business ,Anti-mitochondrial antibody ,type II respiratory failure - Abstract
A 56-year-old woman presenting with type II respiratory failure was transferred to our hospital. She did not exhibit muscle weakness or elevated serum myogenic enzymes, but needle electromyography revealed myogenic changes in the limb muscles, and her blood tests were positive for anti-mitochondrial antibodies (AMA). Muscle histopathological findings included immune-mediated necrotizing myopathy, so she was diagnosed with inflammatory myopathy associated with AMA. After treatment with corticosteroids and noninvasive positive pressure ventilation, her symptoms improved. If a diagnosis of type II respiratory failure is difficult, inflammatory myopathy associated with AMA should be considered as a differential diagnosis.
- Published
- 2021
22. ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: A systematic review and meta-analysis
- Author
-
Jay Prakash, Pradip Kumar Bhattacharya, Lal Chand Tudu, Amit Kumar, K. Prasad, and Arun Kumar Yadav
- Subjects
medicine.medical_specialty ,Cochrane Library ,Critical Care and Intensive Care Medicine ,medicine.disease_cause ,Article ,ROX index ,Internal medicine ,medicine ,Cannula ,Humans ,Prospective Studies ,Prospective cohort study ,Acute hypoxemic respiratory failure ,Retrospective Studies ,Noninvasive Ventilation ,SARS-CoV-2 ,business.industry ,Oxygen Inhalation Therapy ,Area under the curve ,COVID-19 ,Retrospective cohort study ,High flow nasal cannula ,Meta-analysis ,Diagnostic odds ratio ,Respiratory Insufficiency ,business ,Nasal cannula - Abstract
Purpose Prediction of high flow nasal cannula (HFNC) failure in COVID-19 patients with acute hypoxemic respiratory failure (AHRF) may improve clinical management and stratification of patients for optimal treatment. We performed a systematic review and meta-analysis to determine performance of ROX index as a predictor of HFNC failure. Materials and methods Systematic search was performed in electronic databases (PubMed, Google Scholar, Web of Science and Cochrane Library) for articles published till 15 June 2021 investigating ROX index as a predictor for HFNC failure. Quality In Prognosis Studies (QUIPS) tool was used to analyze risk of bias for prognostic factors, by two independent authors. Results Eight retrospective or prospective cohort studies involving 1301 patients showed a good discriminatory value, summary area under the curve (sAUC) 0.81 (95% CI, 0.77–0.84) with sensitivity of 0.70 (95% CI, 0.59–0.80) and specificity of 0.79 (95% CI, 0.67–0.88) for predicting HNFC failure. The positive and negative likelihood ratio were 3.0 (95% CI, 2.2–5.3) and 0.37 (95% CI, 0.28–0.50) respectively, and was strongly associated with a promising predictive accuracy (Diagnostic odds ratio (DOR) 9, 95% CI, 5–16). Conclusion This meta-analysis suggests ROX index has good discriminating power for prediction of HFNC failure in COVID-19 patients with AHRF.
- Published
- 2021
23. An Evidence-Based Protocol for Manual Prone Positioning of Patients With ARDS
- Author
-
Cynthia Fine, Patrick B. Ryan, and Christine E DeForge
- Subjects
Mechanical ventilation ,Protocol (science) ,Respiratory Distress Syndrome ,ARDS ,medicine.medical_specialty ,Evidence-based practice ,business.industry ,medicine.medical_treatment ,MEDLINE ,General Medicine ,CINAHL ,Critical Care Nursing ,medicine.disease ,Respiration, Artificial ,Patient Positioning ,law.invention ,Prone position ,Randomized controlled trial ,law ,Emergency medicine ,Prone Position ,Humans ,Medicine ,Respiratory Insufficiency ,business - Abstract
Background Manual prone positioning has been shown to reduce mortality among patients with moderate to severe acute respiratory distress syndrome, but it is associated with a high incidence of pressure injuries and unplanned extubations. This study investigated the feasibility of safely implementing a manual prone positioning protocol that uses a dedicated device. Review of Evidence A search of CINAHL and Medline identified multiple randomized controlled trials and meta-analyses that demonstrated both the reduction of mortality when prone positioning is used for more than 12 hours per day in patients with acute respiratory distress syndrome and the most common complications of this treatment. Implementation An existing safe patient-handling device was modified to enable staff to safely perform manual prone positioning with few complications for patients receiving mechanical ventilation. All staff received training on the protocol and use of the device before implementation. Evaluation This study included 36 consecutive patients who were admitted to the medical intensive care unit at a large academic medical center because of hypoxemic respiratory failure/acute respiratory distress syndrome and received mechanical ventilation and prone positioning. Data were collected on clinical presentation, interventions, and complications. Sustainability Using the robust protocol and the low-cost device, staff can safely perform a low-volume, high-risk maneuver. This method provides cost savings compared with other prone positioning methods. Conclusions Implementing a prone positioning protocol with a dedicated device is feasible, with fewer complications and lower costs than anticipated.
- Published
- 2021
24. Mortality and Healthcare Use of Patients with Compensated Hypercapnia
- Author
-
Matthew W Wilson, Wassim W. Labaki, and Philip J. Choi
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,Healthcare use ,medicine.medical_specialty ,Acute hypercapnic respiratory failure ,Disease ,Hypercapnia ,Humans ,Medicine ,Intensive care medicine ,Aged ,business.industry ,Carbon Dioxide ,Middle Aged ,Hypoventilation ,Intensive Care Units ,Female ,Noninvasive ventilation ,Blood Gas Analysis ,medicine.symptom ,Respiratory Insufficiency ,business ,Delivery of Health Care ,Chronic respiratory failure - Abstract
Rationale: Acute hypercapnic respiratory failure has been shown to be associated with worse outcomes for various disease states, but less is known about patients with compensated hypercapnic respir...
- Published
- 2021
25. Results of the home mechanical ventilation national program among adults in Chile between 2008 and 2017
- Author
-
Patricia Rivas, Sandra Zapata, María Elena Torres, Ángela Venegas, Marianela Andrade, Jorge Villalobos, Cesar Maquilon, Krishnna Canales, Carmen Andrade, Cristian Olave, Nicolás Valdés, Claudio Rabec, Miguel Aguayo, Monica Antolini, and Osvaldo Cabrera
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Neuromuscular disease ,medicine.medical_treatment ,Respiratory Tract Diseases ,Young Adult ,Diseases of the respiratory system ,Quality of life ,Internal medicine ,medicine ,Humans ,Chronic respiratory failure ,Prospective Studies ,Chile ,Prospective cohort study ,Survival rate ,Aged ,Mechanical ventilation ,Obesity hypoventilation syndrome ,COPD ,Long term ventilation ,RC705-779 ,business.industry ,Research ,Middle Aged ,medicine.disease ,Home Care Services ,Respiration, Artificial ,Home mechanical ventilation ,Quality of Life ,Female ,Domiciliary ventilation ,Respiratory Insufficiency ,business ,Body mass index - Abstract
Background Home mechanical ventilation (HMV) is a viable and effective strategy for patients with chronic respiratory failure (CRF). The Chilean Ministry of Health started a program for adults in 2008. Methods This study examined the following data from a prospective cohort of patients with CRF admitted to the national HMV program: characteristics, mode of admission, quality of life, time in the program and survival. Results A total of 1105 patients were included. The median age was 59 years (44–58). Women accounted for 58.1% of the sample. The average body mass index (BMI) was 34.9 (26–46) kg/m2. A total of 76.2% of patients started HMV in the stable chronic mode, while 23.8% initiated HMV in the acute mode. A total of 99 patients were transferred from the children's program. There were 1047 patients on non-invasive ventilation and 58 patients on invasive ventilation. The median baseline PaCO2 level was 58.2 (52–65) mmHg. The device usage time was 7.3 h/d (5.8–8.8), and the time in HMV was 21.6 (12.2–49.5) months. The diagnoses were COPD (35%), obesity hypoventilation syndrome (OHS; 23.9%), neuromuscular disease (NMD; 16.3%), non-cystic fibrosis bronchiectasis or tuberculosis (non-CF BC or TBC; 8.3%), scoliosis (5.9%) and amyotrophic lateral sclerosis (ALS; 5.24%). The baseline score on the Severe Respiratory Insufficiency questionnaire (SRI) was 47 (± 17.9) points and significantly improved over time. The lowest 1- and 3-year survival rates were observed in the ALS group, and the lowest 9-year survival rate was observed in the non-CF BC or TB and COPD groups. The best survival rates at 9 years were OHS, scoliosis and NMD. In 2017, there were 701 patients in the children's program and 722 in the adult´s program, with a prevalence of 10.4 per 100,000 inhabitants. Conclusion The most common diagnoses were COPD and OHS. The best survival was observed in patients with OHS, scoliosis and NMD. The SRI score improved significantly in the follow-up of patients with HMV. The prevalence of HMV was 10.4 per 100,000 inhabitants. Trial registration This study was approved by and registered at the ethics committee of North Metropolitan Health Service of Santiago, Chile (N° 018/2021).
- Published
- 2021
26. Impairment of Lung Function Increases the Risk of Postoperative Respiratory Failure for Esophageal Carcinoma: A Systematic Review and Meta-Analysis
- Author
-
Ying Zhu and Yanming Sun
- Subjects
Medicine (General) ,medicine.medical_specialty ,Esophageal Neoplasms ,Article Subject ,Biomedical Engineering ,Health Informatics ,Subgroup analysis ,Pulmonary function testing ,R5-920 ,Internal medicine ,Medical technology ,medicine ,Carcinoma ,Humans ,R855-855.5 ,Lung ,Lung function ,business.industry ,Esophageal cancer ,medicine.disease ,Random effects model ,Respiratory failure ,Meta-analysis ,Surgery ,Respiratory Insufficiency ,business ,Research Article ,Biotechnology - Abstract
Objective. To study lung function impairment by meta-analysis to increase the risk of postoperative respiratory failure in patients with esophageal carcinoma. Methods. We searched PubMed, ScienceDirect, and CNKI and other databases, and the search time was set to the time the database was established. We screened the relevant literature to study the relationship between lung function damage and postoperative respiratory failure in patients with esophageal cancer, determined to include the literature and extracted relevant data, and then, applied NOS. The scale evaluates the quality of the literature, and the ReviewManager software was used to perform meta-analysis on the extracted data. Results. Finally, 9 related articles and 2822 research subjects were included, and the average score of literature quality was 5.78 points, the heterogeneity of the literature was large (I2 = 84%), the random effects model was used for analysis, and the correlation between the two showed SMD = 0.09, 95%CI[−0.09, 0.31], Z = 1.10, P = 0.27, which is consistent with the results of the subgroup analysis. Conclusion. The results of the study show that lung function impairment has a positive relationship with postoperative respiratory failure in patients with esophageal cancer. Pulmonary function impairment in cases with different case characteristics can also aggravate the severity of respiratory failure.
- Published
- 2021
27. Assessing Symptom Burden and Depression in Subjects With Chronic Respiratory Insufficiency
- Author
-
Heidi A Rantala, Sirpa Leivo-Korpela, Lauri Lehtimäki, Juho T. Lehto, Tampere University, Department of Respiratory medicine, Dermatology and Allergology, Clinical Medicine, and Department of Oncology
- Subjects
medicine.medical_specialty ,Palliative care ,3121 Internal medicine ,Xerostomia ,Interquartile range ,Neoplasms ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Respiratory system ,Depression (differential diagnoses) ,Retrospective Studies ,Chronic respiratory insufficiency ,Receiver operating characteristic ,Depression ,business.industry ,Palliative Care ,Retrospective cohort study ,General Medicine ,3126 Surgery, anesthesiology, intensive care, radiology ,Dyspnea ,Symptom Assessment ,Respiratory Insufficiency ,business ,Psychosocial - Abstract
Objectives: Patients with chronic respiratory insufficiency suffer from advanced disease, but their overall symptom burden is poorly described. We evaluated the symptoms and screening of depression in subjects with chronic respiratory insufficiency by using the Edmonton symptom assessment system (ESAS). Methods: In this retrospective study, 226 subjects with chronic respiratory insufficiency answered the ESAS questionnaire measuring symptoms on a scale from 0 (no symptoms) to 10 (worst possible symptom), and the depression scale (DEPS) questionnaire, in which the cut-off point for depressive symptoms is 9. Results: The most severe symptoms measured with ESAS (median [interquartile range]) were shortness of breath 4.0 (1.0-7.0), dry mouth 3.0 (1.0-7.0), tiredness 3.0 (1.0-6.0), and pain on movement 3.0 (0.0-6.0). Subjects with a chronic obstructive pulmonary disease as a cause for chronic respiratory insufficiency had significantly higher scores for shortness of breath, dry mouth, and loss of appetite compared to others. Subjects with DEPS ≥9 reported significantly higher symptom scores in all ESAS categories than subjects with DEPS
- Published
- 2021
28. Effect of postoperative administration of inhaled nitric oxide combined with high‐frequency oscillatory ventilation in infants with acute hypoxemic respiratory failure and pulmonary hypertension after congenital heart surgery: A retrospective cohort study
- Author
-
Yi-Rong Zheng, Wen-Peng Xie, Yu-Qing Lei, Hua Cao, Qiang Chen, and Shu-Ting Huang
- Subjects
Heart Defects, Congenital ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Oxygenation index ,Hypertension, Pulmonary ,medicine.medical_treatment ,Nitric Oxide ,medicine.artery ,Administration, Inhalation ,medicine ,Humans ,Adverse effect ,Retrospective Studies ,Mechanical ventilation ,business.industry ,Infant ,Retrospective cohort study ,Oxygenation ,medicine.disease ,Pulmonary hypertension ,Surgery ,Pulmonary artery ,Coronary care unit ,Respiratory Insufficiency ,Cardiology and Cardiovascular Medicine ,business - Abstract
OBJECTIVE To evaluate the effect of inhaled nitric oxide (iNO) combined with high-frequency oscillatory ventilation (HFOV) in the treatment of infants with acute hypoxemic respiratory failure (AHRF) and pulmonary hypertension (PH) after congenital heart surgery. METHODS A retrospective study was conducted on 63 infants with AHRF and PH after congenital heart surgery in our cardiac intensive care unit (CICU) from January 2020 to March 2021. A total of 24 infants in the A group were treated with HFOV combined with iNO, and 39 infants in the B group were treated with HFOV. Relevant clinical data were collected. RESULTS Comparing the two groups, the improvement of the oxygenation index, PaO2 and PaO2 /FiO2 was more obvious for patients in the A group than for those in the B group after intervention (p
- Published
- 2021
29. Clinical, pathological, and molecular genetic analysis of 7 Chinese patients with hereditary myopathy with early respiratory failure
- Author
-
Ling Xu, Chuanzhu Yan, Bing Zhao, Tingjun Dai, Dandan Zhao, Pengfei Lin, Xiaoqing Lv, and Wei Jiang
- Subjects
Pathology ,medicine.medical_specialty ,Dermatology ,Sarcomere ,Exon ,Muscular Diseases ,Genotype ,medicine ,Humans ,Muscle, Skeletal ,Myopathy ,Molecular Biology ,Pathological ,Allele frequency ,Retrospective Studies ,biology ,business.industry ,Genetic Diseases, Inborn ,General Medicine ,Psychiatry and Mental health ,Mutation ,biology.protein ,Immunohistochemistry ,Titin ,Neurology (clinical) ,medicine.symptom ,Respiratory Insufficiency ,business - Abstract
Hereditary myopathy with early respiratory failure (HMERF) is a subtype of myofibrillar myopathy. Mutations located on exon 344 of the titin-A band, the 119th fibronectin-3 domain (FN3 119), are responsible for HMERF. In this article, we retrospectively analyzed the clinical features, findings of muscle imaging, muscle pathology, immunohistochemistry, and ultrastructural characteristics of seven patients diagnosed with HMERF at a single center in China. Muscle MRI showed the involvement of semitendinosus in four patients. The common pathological features were variability in fiber diameter, increased internal nuclei, endomysial fibrosis, and cytoplasmic bodies. On immunohistochemical examination, the cytoplasmic bodies stained positive for calpain-3, p53, and programmed death-ligand 1. Electron microscopy showed cytoplasmic bodies, distorted sarcomere architecture, glycogen pool, and subsarcolemmal accumulation of mitochondria and lysosomes. We retrospectively reviewed four reported HMERF patients in China. Among the 11 patients, the median age at onset was 34 years (range 14–54). Allelic frequency of mutation c.95195C > T was 36.36%. This study characterizes the phenotype and genotype spectrum of HMERF in China.
- Published
- 2021
30. Increase in Chondroitin Sulfate and Decline in Arylsulfatase B May Contribute to Pathophysiology of COVID-19 Respiratory Failure
- Author
-
Alexandar Tzankov, Joanne K. Tobacman, Sumit Bhattacharyya, and Kumar Kotlo
- Subjects
Arylsulfatase B ,medicine.medical_specialty ,Sulfotransferase ,Vascular smooth muscle ,N-Acetylgalactosamine-4-Sulfatase ,Pathology and Forensic Medicine ,chemistry.chemical_compound ,Sulfation ,Internal medicine ,medicine ,Humans ,Chondroitin ,Chondroitin sulfate ,Molecular Biology ,Glycosaminoglycans ,Membrane Glycoproteins ,Chemistry ,Chondroitin Sulfates ,Carbohydrate sulfotransferase ,COVID-19 ,Cell Biology ,General Medicine ,Endocrinology ,Sulfotransferases ,Respiratory Insufficiency ,Immunostaining - Abstract
Introduction: The potential role of accumulation of chondroitin sulfates (CSs) in the pathobiology of COVID-19 has not been examined. Accumulation may occur by increased synthesis or by decline in activity of the enzyme arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) which requires oxygen for activity. Methods: Immunostaining of lung tissue from 28 patients who died due to COVID-19 infection was performed for CS, ARSB, and carbohydrate sulfotransferase (CHST)15. Measurements of mRNA expression of CHST15 and CHST11, sulfotransferase activity, and total sulfated glycosaminoglycans (GAGs) were determined in human vascular smooth muscle cells following angiotensin (Ang) II treatment. Results: CS immunostaining showed increase in intensity and distribution, and immunostaining of ARSB was diminished in COVID-19 compared to normal lung tissue. CHST15 immunostaining was prominent in vascular smooth muscle cells associated with diffuse alveolar damage due to COVID-19 or other causes. Expression of CHST15 and CHST11 which are required for synthesis of CSE and chondroitin 4-sulfate, total sulfated GAGs, and sulfotransferase activity was significantly increased following AngII exposure in vascular smooth muscle cells. Expression of Interleukin-6 (IL-6), a mediator of cytokine storm in COVID-19, was inversely associated with ARSB expression. Discussion/Conclusion: Decline in ARSB and resulting increases in CS may contribute to the pathobiology of COVID-19, as IL-6 does. Increased expression of CHSTs following activation of Ang-converting enzyme 2 may lead to buildup of CSs.
- Published
- 2021
31. Nasal high flow therapy use in wards in patients with chronic obstructive pulmonary disease may spare ICU resources
- Author
-
Matthew W Trump, Matt Taylor, Julie A Jackson, Trevor W Oetting, Kate Branick, Carol A Pelaez, and Iaswarya Ganapathiraju
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,law.invention ,Cohort Studies ,Pulmonary Disease, Chronic Obstructive ,law ,medicine ,Humans ,Immunology and Allergy ,Genetics (clinical) ,Retrospective Studies ,Mechanical ventilation ,business.industry ,Oxygen Inhalation Therapy ,Emergency department ,Respiration, Artificial ,Intensive care unit ,Hospitals ,Intensive Care Units ,Respiratory failure ,Emergency medicine ,Respiratory Insufficiency ,High flow ,business ,Body mass index ,Cohort study - Abstract
Nasal high flow therapy has been previously studied for the management of acute hypoxic respiratory failure in patients with chronic obstructive pulmonary disease but the data regarding its use outside of the intensive care unit are sparse. We aimed to evaluate safety and efficacy of nasal high flow therapy outside of the intensive care unit in patients with acute hypoxic respiratory failure and known chronic obstructive pulmonary disease. We conducted a retrospective matched historic cohort study of adult patients with diagnosed chronic obstructive pulmonary disease presenting with acute hypoxic respiratory failure between December 2017 to June 2019, after the initiation of a new protocol, which allowed patients to be managed with nasal high flow therapy on the medical/surgical wards instead of transferring them to the ICU per prior standard of care. Nasal high flow therapy was initiated either in the emergency department or on the medical/surgical wards. Patients were matched with historical cohorts who were managed with prior standard of care based on age, body mass index, comorbidities, and home oxygen use. Primary outcome of interest was difference in rates of mechanical ventilation. Secondary outcomes included hospital length of stay, total number of days spent in the intensive care unit, and in-hospital mortality. A total of 90 patients met study inclusion criteria and were matched to 90 historical control patients. Among the study group, 8% required mechanical ventilation versus 9% in the control group (p = 0.79). Hospital length of stay was 7 days in study group versus 6 days in control group (p = 0.02), and in-hospital mortality was the same in both study and control groups at 12% (p = 0.99). Nineteen percent of study group patients required ICU level of care at any time during the admission compared with 49% of control group (p
- Published
- 2021
32. Initial experience with CytoSorb therapy in patients receiving left ventricular assist devices
- Author
-
Alexander Weymann, Jef Van den Eynde, Bastian Schmack, Markus Kamler, Arian Arjomandi Rad, Arjang Ruhparwar, Lukas Goerdt, Konstantin Zhigalov, Peter Luedike, Alina Zubarevich, Robert Vardanyan, Michel Pompeu Barros de Oliveira Sá, Nikolaus Pizanis, Thomas Chrosch, and Achim Koch
- Subjects
Male ,medicine.medical_specialty ,Respiration, Artificial/statistics & numerical data ,medicine.medical_treatment ,Tracheotomy/statistics & numerical data ,Medizin ,Biomedical Engineering ,Medicine (miscellaneous) ,Bioengineering ,medicine.disease_cause ,Biomaterials ,C-Reactive Protein/analysis ,Leukocyte Count ,Extracorporeal blood purification ,Internal medicine ,medicine ,Overall survival ,Humans ,In patient ,Hospital Mortality ,Artificial/statistics & numerical data ,Adverse effect ,Retrospective Studies ,Heart Failure ,Mechanical ventilation ,Interleukin-6 ,business.industry ,Respiration ,General Medicine ,Middle Aged ,Immune dysregulation ,medicine.disease ,Respiration, Artificial ,Heart-Assist Devices/adverse effects ,Hemofiltration/instrumentation ,C-Reactive Protein ,Treatment Outcome ,Respiratory failure ,Heart failure ,Heart Failure/therapy ,Cardiology ,Female ,Heart-Assist Devices ,Interleukin-6/blood ,Hemofiltration ,Tracheotomy ,Respiratory Insufficiency ,business - Abstract
BACKGROUND: The use of left ventricular assist devices (LVAD) in patients with advance heart failure is still associated with an important risk of immune dysregulation and infections. The aim of this study was to determine whether extracorporeal blood purification using the CytoSorb device benefits patients after LVAD implantation in terms of complications and overall survival.MATERIALS AND METHODS: Between August 2010 and January 2020, 207 consecutive patients underwent LVAD implantation, of whom 72 underwent CytoSorb therapy and 135 did not. Overall survival, major adverse events, and laboratory parameters were compared between 112 propensity score-matched patients (CytoSorb: 72 patients; non-CytoSorb: 40 patients).RESULTS: WBC (p = .033), CRP (p = .001), and IL-6 (p < .001), significantly increased with LVAD implantation, while CytoSorb did not influence this response. In-hospital mortality and overall survival during follow-up were similar with CytoSorb. However, patients treated with CytoSorb were more likely to develop respiratory failure (54.2% vs. 30.0%, p = .024), need mechanical ventilation for longer than 6 days post-implant (50.0% vs. 27.5%, p = .035), and require tracheostomy during hospitalization (31.9% vs. 12.5%, p = .040). No other significant differences were observed with regard to major adverse events during follow-up.CONCLUSIONS: Overall, our results showed that CytoSorb might not convey a significant morbidity or mortality benefit for patients undergoing LVAD implantation.
- Published
- 2021
33. Hospital Variation in Non-Invasive Ventilation Use for Acute Respiratory Failure Due to COPD Exacerbation
- Author
-
Brice Beck, Spyridon Fortis, Yubo Gao, Mary Vaughan Sarrazin, Amy M.J. O'Shea, and Peter J. Kaboli
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,International Journal of Chronic Obstructive Pulmonary Disease ,Pulmonary Disease, Chronic Obstructive ,Interquartile range ,Severity of illness ,Epidemiology ,medicine ,Humans ,Non-invasive ventilation ,Hospital Mortality ,Retrospective Studies ,Original Research ,pulmonary disease ,Mechanical ventilation ,COPD ,Noninvasive Ventilation ,chronic obstructive ,business.industry ,non-invasive ventilation ,General Medicine ,medicine.disease ,Respiration, Artificial ,Hospitals ,Quartile ,Emergency medicine ,Breathing ,epidemiology ,Respiratory Insufficiency ,business - Abstract
Spyridon Fortis,1,2 Yubo Gao,1,3 Amy M J OâShea,1,3 Brice Beck,1 Peter Kaboli,1,3 Mary Vaughan Sarrazin1,3 1Center for Access & Delivery Research & Evaluation (CADRE), Iowa City VA Health Care System, Iowa City, IA, USA; 2Department of Internal Medicine, Division of Pulmonary, Critical Care and Occupation Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, USA; 3Department of Internal Medicine, Division of General Internal Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, USACorrespondence: Spyridon FortisDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Occupation Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive â C33 GH, Iowa City, IA, 52242, USAEmail spyridon-fortis@uiowa.eduBackground: Non-invasive mechanical ventilation (NIV) use in patients admitted with acute respiratory failure due to COPD exacerbations (AECOPDs) varies significantly between hospitals. However, previous literature did not account for patientsâ illness severity. Our objective was to examine the variation in risk-standardized NIV use after adjusting for illness severity.Methods: We retrospectively analyzed AECOPD hospitalizations from 2011 to 2017 at 106 acute-care Veterans Health Administration (VA) hospitals in the USA. We stratified hospitals based on the percentage of NIV use among patients who received ventilation support within the first 24 hours of admission into quartiles, and compared patient characteristics. We calculated the risk-standardized NIV % using hierarchical models adjusting for comorbidities and severity of illness. We then stratified the hospitals by risk-standardized NIV % into quartiles and compared hospital characteristics between quartiles. We also compared the risk-standardized NIV % between rural and urban hospitals.Results: In 42,048 admissions for AECOPD over 6 years, the median risk-standardized initial NIV % was 57.3% (interquartile interval [IQI]=41.9â 64.4%). Hospitals in the highest risk-standardized NIV % quartiles cared for more rural patients, used invasive ventilators less frequently, and had longer length of hospital stay, but had no difference in mortality relative to the hospitals in the lowest quartiles. The risk-standardized NIV % was 65.3% (IQI=34.2â 84.2%) in rural and 55.1% (IQI=10.8â 86.6%) in urban hospitals (p=0.047), but hospital mortality did not differ between the two groups.Conclusion: NIV use varied significantly across hospitals, with rural hospitals having higher risk-standardized NIV % rates than urban hospitals. Further research should investigate the exact mechanism of variation in NIV use between rural and urban hospitals.Keywords: pulmonary disease, chronic obstructive, epidemiology, non-invasive ventilation
- Published
- 2021
34. Nurses' Ability to Recognize and Prevent Opioid-Induced Respiratory Depression
- Author
-
Molly A. McNaughton, Patricia Finch-Guthrie, Leslie F. Maynard, Amanda Aplin, Amanda Kautza-Farley, Meghan Schenian, and Jamie Lundberg
- Subjects
Advanced and Specialized Nursing ,Pain, Postoperative ,medicine.medical_specialty ,Evidence-based practice ,business.industry ,Nurses ,Sedation scale ,Usability ,Patient assessment ,Analgesics, Opioid ,Opioid ,medicine ,Physical therapy ,Humans ,Acute postoperative pain ,Orthopedics and Sports Medicine ,Clinical Competence ,Respiratory Insufficiency ,business ,Depression (differential diagnoses) ,Dose selection ,medicine.drug - Abstract
Opioids are the primary therapy for acute postoperative pain, despite being associated with opioid-induced respiratory depression (OIRD). The purpose of this study was to improve nurses' knowledge, confidence, and ability to recognize, prevent, and treat OIRD in postoperative inpatients and evaluate the feasibility of using the Pasero Opioid-Induced Sedation Scale (POSS). Registered nurses completed three tools: (1) an Opioid Knowledge Self-Assessment, which was administered pre- and post-education; (2) a Confidence Scale, which was administered pre- and post-education; and (3) a POSS Perceptions and Usability Scale that was administered post-education. Nurses were educated on the POSS and then immediately following the training practiced by undertaking a patient assessment using the instrument. They then completed the POSS Perceptions and Usability Scale to rate their perception of the feasibility of using the POSS. Between preeducation and posteducation, participant knowledge increased in the following areas: recognizing opioid-induced side effects, dose selection, risk factors for oversedation, and information to make clinical decisions. However, there was a drop in scores when asked about knowledge of who is at risk for opioid-related side effects. These findings support our conclusion that OIRD education improves nursing confidence and knowledge. There was significant agreement between the nurse and subject matter experts POSS scores, indicating that this tool is easy to use.
- Published
- 2021
35. Characteristics of prolonged noninvasive ventilation in emergency departments and impact upon effectiveness. Analysis of the VNICat registry
- Author
-
O. García-Trallero, M. Sancho-Ramoneda, Maria Arranz, Javier Jacob, J.R. Cousiño-Chao, Antonio German, J. Farré-Cerdà, Àngels Lopez, M.C. Navarro-Sáez, X. López-Altimiras, José Zorrilla, and F. López i Vengut
- Subjects
medicine.medical_specialty ,Noninvasive Ventilation ,business.industry ,General Medicine ,Cohort Studies ,Emergency medicine ,medicine ,Humans ,Prolonged ventilation ,Noninvasive ventilation ,Observational study ,Prospective Studies ,Registries ,Emergency Service, Hospital ,Respiratory Insufficiency ,business ,Cohort study - Abstract
To analyze the characteristics and variables associated with prolonged noninvasive ventilation performed completely in Emergency Departments (NIV-ED) and its influence upon effectiveness.A prospective, multicenter, observational multipurpose cohort study was carried out.VNICat Registry.Patients in which NIV-ED was performed in 11 Catalan hospitals in the months of February or March 2015.No.The study variable was NIV-ED, which as a function of time was defined as prolonged or not prolonged. The efficacy variable was the success of the technique in terms of patient improvement.A total of 125 patients were included, with a median NIV-ED duration of 12hours, which was the cut-off point for the comparator groups. In 60 cases (48%) NIV-ED was not prolonged (12hours), while in 65 cases (52%) ventilation was prolonged (≥12hours). Non-prolonged NIV-ED was associated to the indication of acute heart failure and prolonged ventilation to the presence of diabetes. There were no differences between non-prolonged and prolonged NIV-ED in terms of efficacy, and the success rate in terms of improvement was 68.3% and 76.9%, respectively, with an adjusted odds ratio of 1.49 (95%CI 0.61-3.60).Prolonged NIV-ED is a frequent situation, but few variables associated to it have been studied. The presence of prolonged ventilation did not influence the success rate of NIV.
- Published
- 2021
36. The Risk of Postoperative Complications After Major Elective Surgery in Active or Resolved COVID-19 in the United States
- Author
-
Chi-Fu Jeffrey Yang, John Z. Deng, Harpal S Sandhu, Janine S Chan, Ya-Wen Chen, David C. Chang, Nikhil Panda, and Alexandra L Potter
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Logistic regression ,Time-to-Treatment ,Sepsis ,surgery ,COVID-19 Testing ,Postoperative Complications ,Risk Factors ,medicine ,Humans ,Elective surgery ,business.industry ,SARS-CoV-2 ,COVID-19 ,Pneumonia ,medicine.disease ,United States ,Surgery ,Pulmonary embolism ,operation ,Increased risk ,Respiratory failure ,Elective Surgical Procedures ,postoperative pulmonary complications ,business ,Pulmonary Embolism ,Respiratory Insufficiency - Abstract
Objective: To assess the association between the timing of surgery relative to the development of Covid-19 and the risks of postoperative complications. Summary Background Data: It is unknown whether patients who recovered from Covid-19 and then underwent a major elective operation have an increased risk of developing postoperative complications. Methods: The risk of postoperative complications for patients with Covid-19 undergoing 18 major types of elective operations in the Covid-19 Research Database was evaluated using multivariable logistic regression. Patients were grouped by time of surgery relative to SARS-CoV-2 infection; that is, surgery performed: (1) before January 1, 2020 (“pre-Covid-19”), (2) 0 to 4 weeks after SARS-CoV-2 infection (“peri-Covid-19”), (3) 4 to 8 weeks after infection (“early post-Covid-19”), and (4) ≥8 weeks after infection (“late post-Covid-19”). Results: Of the 5479 patients who met study criteria, patients with peri-Covid-19 had an elevated risk of developing postoperative pneumonia [adjusted odds ratio (aOR), 6.46; 95% confidence interval (CI): 4.06–10.27], respiratory failure (aOR, 3.36; 95% CI: 2.22–5.10), pulmonary embolism (aOR, 2.73; 95% CI: 1.35–5.53), and sepsis (aOR, 3.67; 95% CI: 2.18–6.16) when compared to pre-Covid-19 patients. Early post-Covid-19 patients had an increased risk of developing postoperative pneumonia when compared to pre-Covid-19 patients (aOR, 2.44; 95% CI: 1.20–4.96). Late post-Covid-19 patients did not have an increased risk of postoperative complications when compared to pre-Covid-19 patients. Conclusions: Major, elective surgery 0 to 4 weeks after SARS-CoV-2 infection is associated with an increased risk of postoperative complications. Surgery performed 4 to 8 weeks after SARS-CoV-2 infection is still associated with an increased risk of postoperative pneumonia, whereas surgery 8 weeks after Covid-19 diagnosis is not associated with increased complications.
- Published
- 2021
37. Novel application of respiratory muscle index obtained from chest computed tomography to predict postoperative respiratory failure after major non-cardiothoracic surgery
- Author
-
Sarah B. Jochum, Dana M. Hayden, Robert A. Balk, Palmi Shah, Emily Hejna, David L Vines, Sarah J. Peterson, Connor Wakefield, and Fadi Hamati
- Subjects
Male ,Sarcopenia ,medicine.medical_specialty ,medicine.medical_treatment ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Predictive Value of Tests ,medicine ,Respiratory muscle ,Humans ,030212 general & internal medicine ,Wasting ,APACHE ,Retrospective Studies ,Mechanical ventilation ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Respiration, Artificial ,Respiratory Muscles ,Respiratory failure ,Cardiothoracic surgery ,Surgical Procedures, Operative ,030220 oncology & carcinogenesis ,Anesthesia ,Breathing ,Female ,Radiography, Thoracic ,Surgery ,medicine.symptom ,Respiratory Insufficiency ,Tomography, X-Ray Computed ,Complication ,business - Abstract
Background Postoperative respiratory failure (PRF) is a serious complication associated with significant morbidity and mortality. We propose a new method to predict PRF by utilizing computed tomography (CT) of the chest to assess degree of respiratory muscle wasting prior to surgery. Methods Patients who received a chest CT and required invasive mechanical ventilation (MV) after major non-cardiothoracic surgery were included. Exclusion criteria included cardiothoracic surgery. Respiratory muscle index (RMI) was calculated at the T6 vertebra measured on Slice-O-Matic® software. Results Thirty three patients met inclusion with a mean (±SD) age, BMI, and APACHE II score of 62.2 years (±12.1), 28.1 kg/m2 (±7.8), and 14.1 (±4.7). Most patients were female (n = 22 [67%]). Eleven patients (33%) developed PRF with a mean of 6.0 (±10.7) initial ventilation days. There was no difference in baseline demographics between groups. RMI values for the PRF group were significantly lower when compared to the non-PRF group: 22.7 cm2/m2 (±5.3) vs. 28.5 cm2/m2 (±5.9) (p = 0.008). Conclusion Presence of respiratory muscle wasting prior to surgery was found to be associated with postoperative respiratory failure.
- Published
- 2021
38. Steroid treatment in patients with acute respiratory distress syndrome: a systematic review and network meta-analysis
- Author
-
Shoichi Ihara, Shunsuke Taito, Masahiko Sakaguchi, Shingo Ohki, Takashi Hongo, Junichi Ishikawa, Shodai Yoshihiro, Tomoaki Yatabe, and Tadashi Kaneko
- Subjects
Adult ,medicine.medical_specialty ,ARDS ,Network Meta-Analysis ,Placebo ,Methylprednisolone ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Hospital Mortality ,Glucocorticoids ,Dexamethasone ,Hydrocortisone ,Respiratory Distress Syndrome ,business.industry ,Incidence (epidemiology) ,medicine.disease ,Critical care ,Anesthesiology and Pain Medicine ,Anesthesia ,Meta-analysis ,Systematic review ,Original Article ,Steroids ,business ,Respiratory insufficiency ,medicine.drug - Abstract
Purpose Although the most recent systematic review and meta-analyses on acute respiratory distress syndrome (ARDS) have shown that the use of steroids decreases mortality in adult patients, its benefits and risks may differ depending on the type and dosage of the steroid. Therefore, we conducted a network meta-analysis (NMA) to compare the differences in the efficacy among different doses and types of steroids. Methods We searched MEDLINE, CENTRAL, ICHUSHI, ClinicalTrials.gov, and WHO ICTRP databases from the earliest records to March 2021 for randomized control trials, which compared steroids with placebo or conventional therapy for ARDS. Using the random-effects model, we compared various categories of steroids (high-dose methylprednisolone, low-dose methylprednisolone, hydrocortisone, dexamethasone, and no steroid) concerning hospital mortality, incidence of infection, and ventilator-free days (VFD). Results We analyzed nine studies involving adult patients (n = 1212). Although there were no significant differences between the groups in terms of the mortality and incidence of infection, the number of VFD were greater when using low-dose methylprednisolone than when not using any steroids (Mean difference: 6.06; 95% confidence intervals: [2.5, 10.5]). Moreover, the rank probability showed that low-dose methylprednisolone might be the optimal treatment, whereas using no steroid or high-dose methylprednisolone may be inferior to other treatments in terms of mortality, infection, and VFD. Conclusion This NMA suggested that the effect of steroids on the outcome in patients with ARDS might depend on the type of the steroid drug administered. Moreover, further studies are needed to identify the optimal type and dosage. Supplementary Information The online version contains supplementary material available at 10.1007/s00540-021-03016-5.
- Published
- 2021
39. A systematic review and meta-analysis of different mask ventilation schemes on management of general anesthesia in patients with respiratory failure
- Author
-
Yu Liu, Yao Li, Xinchuan Wei, Lili Tian, Bin Cai, Xiangkui Li, Jiyue You, and Qian Lei
- Subjects
Advanced and Specialized Nursing ,Respiratory Distress Syndrome ,medicine.medical_specialty ,Noninvasive Ventilation ,Mask ventilation ,business.industry ,Anesthesia, General ,Respiration, Artificial ,Anesthesiology and Pain Medicine ,Respiratory failure ,Meta-analysis ,medicine ,Humans ,In patient ,Respiratory Insufficiency ,Intensive care medicine ,business - Abstract
Difficulty in mask ventilation is one of the more dangerous factors in general anesthesia. The traditional mask has some problems, such as air leakage and facial skin compression injury. The head cover is a new interactive non-invasive ventilation (NIV) model. NIV studies comparing hoods and masks have all been single-center and small-sample randomized trials, and extensive clinical studies are lacking.We conducted a computerized search in the databases of PubMed, Embase, Medline, Chinese Biomedical Literature (CBM), and others for randomized controlled trials (RCTs) on the effect of hoods and masks on patients with respiratory failure published since their establishment to March 2021. The quality of the included literature was assessed using the Cochrane Systematic Review Manual, and the data was analyzed using Review Manager 5.3 to assess the risk of bias.A total of 9 articles were included, involving 462 patients, with 233 patients in the hood group and 229 patients in the face mask group. The results of meta-analysis showed the comparative endotracheal intubation rate of the hood group and the mask group [odds ratio (OR) =0.26; 95% confidence interval (CI): 0.14 to 0.47; Z=4.48; P0.00001], the complications rate (OR =0.54; 95% CI: 0.31 to 0.97; Z=2.08; P=0.04) was statistically considerable, although there was no considerable difference in in-hospital mortality (OR =0.56; 95% CI: 0.28 to 1.14; Z=1.59; P=0.11).NIV with a hood can reduce the rate of endotracheal intubation and the incidence of related complications in patients with acute respiratory failure (ARF), which has considerable advantages in contrast to the traditional mask.
- Published
- 2021
40. Circulating levels of calprotectin, a signature of neutrophil activation in prediction of severe respiratory failure in COVID-19 patients: a multicenter, prospective study (CalCov study)
- Author
-
Lourdes Albert-Botella, María Dolores Rodríguez Mulero, Leonor Nogales Martín, María José Fora Romero, Lucía Fernández Presa, Luis García de Guadiana-Romualdo, María Dolores Calvo, Marta Hernández Olivo, Ana Belen López Tarazaga, Isabel Llompart-Alabern, Cristina Bolado Jiménez, Edwin R Puerto-Lara, Leyre Pinilla Arribas, Celia Juez Santamaría, María Galindo Martínez, Aleksandra Mandic Havelka, Andrea Ballester Férriz, Valerio Campos-Rodríguez, Enrique Rodríguez-Borja, María Dolores Albaladejo-Otón, Carlos Rodríguez Rojas, Virginia Espinilla Fernández, Alexandra M Guiu-Martí, María Salomé Ros Braquehais, Wysalli Trapiello Fernández, Adela Pozo Giraldez, David Andaluz-Ojeda, Daniel Morell-Garcia, Juan Ortega-Pérez, and Antonieta Ballesteros-Vizoso
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multivariate analysis ,Adolescent ,Neutrophils ,medicine.medical_treatment ,Immunology ,Neutrophil Activation ,law.invention ,Young Adult ,fluids and secretions ,Predictive Value of Tests ,law ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Original Research Article ,Invasive mechanical ventilation ,Prospective cohort study ,Aged ,Aged, 80 and over ,Inflammation ,Pharmacology ,Mechanical ventilation ,Calprotectin ,ICU admission ,business.industry ,COVID-19 ,Emergency department ,Middle Aged ,Respiration, Artificial ,Intensive care unit ,Intensive Care Units ,Treatment Outcome ,ROC Curve ,Respiratory failure ,Area Under Curve ,Immune System ,Multivariate Analysis ,Population study ,Female ,Respiratory Insufficiency ,business ,Leukocyte L1 Antigen Complex - Abstract
OBJECTIVE: Severe COVID-19 is characterized by a dysregulated immune response in which neutrophils play a critical role. Calprotectin reflects neutrophil activation and is involved in the self-amplifying thrombo-inflammatory storm in severe COVID-19. We aimed to evaluate the role of calprotectin in early prediction of severity in COVID-19 patients. METHODS: This was a multicenter prospective observational study enrolling consecutive adult COVID-19 patients. On arrival to emergency department, blood samples were collected for laboratory tests, including serum calprotectin. The primary outcome was severe respiratory failure requiring invasive mechanical ventilation and the secondary outcome was need for Intensive Care Unit (ICU) admission. RESULTS: Study population included 395 patients, 57 (14.4%) required invasive mechanical ventilation and 100 (25.3%) were admitted to ICU. Median serum calprotectin levels were significantly higher in intubated (3.73mg/L vs. 2.63mg/L; p
- Published
- 2021
41. Acute Hypoxemic Respiratory Failure with High Clinical Suspicion of COVID-19 Despite Negative PCR: a Case for Empiric Corticosteroids and Role of Serum Antibody in Diagnosis
- Author
-
James W. Leatherman, Heidi A. Erickson, and Vannesa Cederstrom
- Subjects
2019-20 coronavirus outbreak ,medicine.medical_specialty ,Acute hypoxemic respiratory failure ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,COVID-19 ,Polymerase Chain Reaction ,Serum antibody ,Clinical Vignette ,Adrenal Cortex Hormones ,Internal medicine ,Internal Medicine ,Humans ,Medicine ,Respiratory Insufficiency ,business - Published
- 2021
42. Lithium toxicity at therapeutic doses as a fallout of COVID-19 infection: a case series and possible mechanisms
- Author
-
Geetha Desai, Sundarnag Ganjekar, Naveen Manohar Pai, Vidhyavathi Malyam, Sydney Moirangthem, and Manisha Murugesan
- Subjects
Male ,medicine.medical_specialty ,Bipolar Disorder ,Lithium (medication) ,medicine.drug_class ,acute renal injury ,Case Reports ,Gastroenterology ,Treatment of bipolar disorder ,Fatal Outcome ,Hyperchloremia ,Antimanic Agents ,Internal medicine ,medicine ,Humans ,Urea ,Pharmacology (medical) ,Bipolar disorder ,Kidney ,Hypernatremia ,SARS-CoV-2 ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Acute kidney injury ,COVID-19 ,lithium therapy ,Mood stabilizer ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,medicine.anatomical_structure ,lithium toxicity ,Creatinine ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Lithium Compounds ,Tachycardia, Ventricular ,Hyperkalemia ,Respiratory Insufficiency ,business ,medicine.drug - Abstract
Supplemental Digital Content is available in the text., Lithium, a mood stabilizer used in the treatment of bipolar disorder is known for its anti-inflammatory properties with the discussion of its potential use in COVID-19 infection. The SARS-CoV-2 virus causing COVID-19 infection is known to enter the target cells through angiotensin converting enzyme-2 receptors present in abundance in the lung and renal tissue. Recent research supports the evidence for direct renal injury by viral proteins. Here we report two patients with bipolar disorder presenting with lithium toxicity in the presence of COVID-19 infection. Two patients with bipolar disorder, maintaining remission on lithium prophylaxis, presented to the psychiatric emergency with recent-onset fever and altered sensorium. Both the patient’s investigations revealed lithium toxicity, elevated serum creatinine, urea and inflammatory markers. Hypernatremia, hyperkalaemia, and hyperchloremia were seen in one patient. Lithium and other psychotropic medications were stopped immediately, and COVID-19 treatment was initiated. Patient with clinical signs of lithium toxicity, hypernatremia, hyperkalaemia, and hyperchloremia developed ventricular tachycardia. He survived and regained consciousness after 2 weeks of aggressive conservative management. However, another patient died of acute respiratory failure on day 3. Possible direct infection of the kidney by SARS-CoV-2 viral proteins can manifest with acute kidney injury and lithium toxicity among patients on long-term lithium therapy. Health professionals treating COVID-19 infection among individuals on lithium therapy should be aware of the possibility of lithium toxicity in the background of renal injury.
- Published
- 2021
43. Incidence and Outcomes of Life-Threatening Events During Hospitalization: A Retrospective Study of Patients Treated with Naloxone
- Author
-
Anne M. Meehan, Darrell R. Schroeder, Juraj Sprung, Diana J Valencia Morales, Toby N. Weingarten, and Mariana L. Laporta
- Subjects
medicine.medical_specialty ,Narcotic Antagonists ,law.invention ,law ,Internal medicine ,Naloxone ,Humans ,Medicine ,Rapid response team ,Depression (differential diagnoses) ,Retrospective Studies ,business.industry ,Incidence ,Incidence (epidemiology) ,Clinical course ,Retrospective cohort study ,General Medicine ,Intensive care unit ,Analgesics, Opioid ,Hospitalization ,Anesthesiology and Pain Medicine ,Opioid ,Neurology (clinical) ,Respiratory Insufficiency ,business ,medicine.drug - Abstract
Background We describe the clinical course of medical and surgical patients who received naloxone on general hospital wards for suspected opioid-induced respiratory depression (OIRD). Methods From May 2018 through October 2020, patients who received naloxone on hospital wards were identified and their records reviewed for incidence and clinical course. Results There were 86,030 medical and 106,807 surgical admissions. Naloxone was administered to 99 (incidence 11.5 [95% confidence interval 9.4–14.0] per 10,000 admissions) medical and 63 (5.9 [95% confidence interval 4.5–7.5]) surgical patients (P Conclusion Medical inpatients are more likely to suffer OIRD than are surgical inpatients despite lower opioid doses. Definitive OIRD was confirmed in 77% of patients because of immediate naloxone response, whereas 23% of patients did not respond, and this subset was more likely to need a higher level of care and had a higher 30-day mortality rate. Careful monitoring of mental and respiratory variables is necessary when opiates are used in hospital.
- Published
- 2021
44. One-Year Readmission Following Undifferentiated Acute Hypercapnic Respiratory Failure
- Author
-
Remi Coudroy, Thomas Piraino, Karen E. A. Burns, Giulia Cavalot, Fernando Vieira, David A. Hall, Laurent Brochard, Vera Dounaevskaia, and Orla Smith
- Subjects
Pulmonary and Respiratory Medicine ,COPD ,medicine.medical_specialty ,Noninvasive Ventilation ,Acute hypercapnic respiratory failure ,business.industry ,Pulmonary disease ,medicine.disease ,Patient Readmission ,Respiratory support ,Hypercapnia ,Pulmonary Disease, Chronic Obstructive ,Emergency medicine ,medicine ,Humans ,Respiratory Insufficiency ,business ,Retrospective Studies - Abstract
Patients with acute hypercapnic respiratory failure (AHRF) often require hospitalization and respiratory support. Early identification of patients at risk of readmission would be helpful. We evaluated 1-y readmission and mortality rates of patients admitted for undifferentiated AHRF and identified the impact of initial severity on clinically important outcomes. We retrospectively analyzed patients who presented with AHRF to the emergency department of St Michael's Hospital in 2017. We collected data about patients' characteristics, hospital admission, readmission and mortality one year after the index admission. We analyzed predictors of readmission and mortality and conducted a survival analysis comparing patients who did and did not receive ventilatory support. A cohort of 212 patients with AHRF who survived their hospital admission were analyzed. At one year, 150 patients (70.8%) were readmitted and 19 (9%) had died. Main diagnoses included chronic obstructive pulmonary disease (60%), congestive heart failure (36%), asthma (22%) and obesity (19%), and these categories of patients had similar 1 y readmission rates. One third had more than one coexisting chronic illness. Although comorbidities were more frequent in readmitted patients, only a history of previous hospital admissions remained associated with 1 y readmission and mortality in multivariate analysis. Need for ventilatory support at admission was not associated with higher 1 y probability of readmission or death. Undifferentiated AHRF is the presentation of multiple chronic illnesses. Patients who survive one episode of AHRF and with previous history of admission have the highest risk of readmission and death regardless of whether they receive ventilatory support during index admission.
- Published
- 2021
45. All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study
- Author
-
Ali A. El-Solh, Yolanda Lawson, and Daniel A. El-Solh
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Respiratory failure ,law.invention ,Cohort Studies ,COVID-19 Testing ,Mechanical ventilation ,law ,Internal medicine ,Internal Medicine ,Risk of mortality ,Humans ,Medicine ,Mortality ,Veterans Affairs ,Aged ,Retrospective Studies ,Veterans ,ICU admission ,business.industry ,Proportional hazards model ,Statins ,COVID-19 ,Intensive care unit ,COVID-19 Drug Treatment ,Im - Original ,Cohort ,Propensity score matching ,Emergency Medicine ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Respiratory Insufficiency ,business ,Cohort study - Abstract
Statins have been advocated as a potential treatment for coronavirus disease-2019 (COVID-19) due to its pleotropic properties. The aim of the study was to elucidate the association between antecedent statin exposure and 30-day all-cause mortality, intensive care unit (ICU) admission and hypoxic respiratory failure requiring mechanical ventilation in patients diagnosed with COVID-19. Observational cohort study derived from the VA Corporate Data Warehouse of all veterans tested positive for COVID-19 between January 1st and May 31st, 2020. Antecedent use of statins was defined as a redeemed drug prescription in the 6 months prior to COVID-19 diagnosis. Propensity-matched mixed-effects logistic regression was performed, stratified by statin use. The study population comprised 14,268 patients with COVID-19 (median age 66 years (25th–75th percentile, 53–74), 90.7% men), of whom 7,168 were receiving a prescription for statins. Patients with statin exposure had a greater prevalence of comorbidities and a higher risk of mortality (Odd ratio [OR] 1.52; 95% confidence interval [CI] 1.37–1.68). After adjusting for covariates, statin exposure was not associated with a decreased mortality in the overall cohort by either Cox proportional hazards stratified model (HR 0.99; 95% CI 0.88–1.12) or propensity matching (HR .86; 95% CI 0.74–1.01). Similarly, there was no demonstrated advantage of statins in reducing the risk of ICU admission (HR 0.92; 95% CI 0.74–1.31) or hypoxic respiratory failure requiring mechanical ventilation (HR 1.02; 95% CI 0.81–1.29). Antecedent statin exposure in patients with COVID-19 was not associated with a decreased risk of 30-day all-cause mortality or need for mechanical ventilation.
- Published
- 2021
46. The impact of <scp>COVID</scp> ‐19 on acute non‐invasive ventilation services: A case for change
- Author
-
Hannah Barnard, Rahul Mukherjee, Alice M Turner, Alastair Watson, Pearlene Antoine-Pitterson, and Bethany Jones
- Subjects
Male ,Pulmonary and Respiratory Medicine ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,critical care medicine ,law.invention ,COVID‐19 ,law ,Commentaries ,medicine ,Humans ,COPD ,Non-invasive ventilation ,Intensive care medicine ,Aged ,clinical trials ,Noninvasive Ventilation ,SARS-CoV-2 ,business.industry ,ventilation ,COVID-19 ,Middle Aged ,medicine.disease ,Respiration, Artificial ,Clinical trial ,clinical respiratory medicine ,Ventilation (architecture) ,Commentary ,Female ,Respiratory Insufficiency ,business - Published
- 2021
47. Acute hypercapnic respiratory failure and its management on the acute medical take
- Author
-
Swapna Mandal, A Saigal, and Amar J Shah
- Subjects
Obesity hypoventilation syndrome ,medicine.medical_specialty ,Noninvasive Ventilation ,Modalities ,Acute hypercapnic respiratory failure ,Inpatient care ,business.industry ,General Medicine ,Respiratory physiology ,Audit ,medicine.disease ,Hospitalization ,Pulmonary Disease, Chronic Obstructive ,medicine ,Breathing ,Humans ,Respiratory Insufficiency ,Intensive care medicine ,business ,Patient comfort - Abstract
Acute hypercapnic respiratory failure accounts for 50 000 hospital admissions each year in the UK. This article discusses the pathophysiology and common causes of acute hypercapnic respiratory failure, and provides practical considerations for patient management in acute medical settings. Non-invasive ventilation for persistent acute hypercapnic respiratory failure is widely recognised to improve patient outcomes and reduce mortality. National audits highlight a need to improve patients' overall care and outcomes through appropriate patient selection and treatment initiation. Multidisciplinary involvement is essential, as this underpins inpatient care and follow up after hospital discharge. New non-invasive ventilation modalities may offer better patient comfort and compensate better for sleep-related changes in respiratory mechanics. Emerging therapies, such as nasal high flow, may offer an alternative treatment approach in those who cannot tolerate non-invasive ventilation, but more research is required to completely understand its effectiveness in treating acute hypercapnic respiratory failure.
- Published
- 2021
48. Determinants of usage and nonadherence to noninvasive ventilation in children and adults with Duchenne muscular dystrophy
- Author
-
Andrew J. Skalsky, Rakesh Bhattacharjee, Jeremy E. Orr, Manju S. Hurvitz, and Daniel J. Lesser
- Subjects
Adult ,musculoskeletal diseases ,Pulmonary and Respiratory Medicine ,Chronic respiratory insufficiency ,medicine.medical_specialty ,Noninvasive Ventilation ,Adolescent ,business.industry ,Duchenne muscular dystrophy ,Vital Capacity ,medicine.disease ,Scientific Investigations ,Muscular Dystrophy, Duchenne ,Young Adult ,Neurology ,Internal medicine ,medicine ,Cardiology ,Humans ,Noninvasive ventilation ,Neurology (clinical) ,Child ,Respiratory Insufficiency ,business ,Retrospective Studies - Abstract
STUDY OBJECTIVES: Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to chronic respiratory insufficiency and failure. Use of home noninvasive ventilation (NIV) has been linked to improved outcomes including reduced mortality. Despite the importance of NIV, factors promoting optimal NIV usage and determinants of nonadherence have not been rigorously examined. Moreover, given that respiratory issues in DMD span between childhood and adulthood, examination across a broad age group is needed. The objectives of this study were to (1) evaluate NIV usage across a broad spectrum of patients with DMD, including both children and adults, and (2) identify biological and socioeconomic determinants of NIV usage and NIV nonadherence. METHODS: We performed a retrospective review of all patients with DMD from February 2016 to February 2020 who underwent evaluation at associated pediatric and adult neuromuscular disease clinics. NIV use was determined objectively from device downloads. A priori, we defined nonadherence as < 4 hours use per night, quantified as the percentage of nights below this threshold across a 30-day period within 6 months of a clinic visit. We also assessed the average hours of NIV usage over this time period. Predictors examined included demographics, social determinants, and pulmonary function. RESULTS: 33 patients with DMD were identified, 29 (87%) of whom were using NIV (13 age < 21 years). Mean age was 22.9 ± 6.6 years (range 13–39 years), body mass index was 23.4 ± 10.4 kg/m(2), and seated forced vital capacity was 23% ± 18% predicted. Mean nightly NIV usage was 7.4 ± 3.8 hours and mean percentage of nonadherent nights was 13% ± 30%. In univariable analysis, age did not predict use. Those with lower forced vital capacity had higher NIV usage hours (P = .01) and a trend toward less nonadherence (P = .06). Higher estimated household income demonstrated a trend toward increased usage hours and less nonadherence (both P = .08). Multivariable analysis found increased usage hours were predicted best by higher income, higher inspiratory positive airway pressure, and higher bicarbonate. Nonadherence was higher in those with lower income or higher forced vital capacity. CONCLUSIONS: In this cohort of adult and pediatric patients with DMD, most individuals were using NIV. While usage hours were higher with lower lung function, substantial variability remains unexplained by examined factors. Nonadherence was observed in some individuals, including those with advanced disease. Further investigations should focus on evaluating patient-oriented outcomes to define optimal NIV usage across the spectrum of disease and determine strategies to counteract issues with nonadherence. CITATION: Hurvitz MS, Bhattacharjee R, Lesser DJ, Skalsky AJ, Orr JE. Determinants of usage and nonadherence to noninvasive ventilation in children and adults with Duchenne muscular dystrophy. J Clin Sleep Med. 2021;17(10):1973–1980.
- Published
- 2021
49. A 50-Year-Old Woman With Shortness of Breath
- Author
-
Chetan Bhardwaj, Padmaraj D. Duvvuri, and Keattiyoat Wattanakit
- Subjects
Liver Cirrhosis ,Pulmonary and Respiratory Medicine ,Pediatrics ,medicine.medical_specialty ,Vascular Malformations ,Hypertension, Pulmonary ,Esophageal and Gastric Varices ,Critical Care and Intensive Care Medicine ,Medication Adherence ,Pulmonary Heart Disease ,Furosemide ,Humans ,Medicine ,Diuretics ,Substance Abuse, Intravenous ,business.industry ,Smoking ,Oxygen Inhalation Therapy ,Middle Aged ,Hepatitis C ,Dyspnea ,Pulmonary Veins ,Azygos Vein ,Female ,Respiratory Insufficiency ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business - Published
- 2021
50. Validation of the Arabic Severe Respiratory Insufficiency Questionnaire
- Author
-
Rania N. Bzeih, Lilian A. Ghandour, Mohamad F. El-Khatib, Salah Zeineldine, Marwan Alawieh, and Abla M. Sibai
- Subjects
Pulmonary and Respiratory Medicine ,Cross-Cultural Comparison ,Male ,medicine.medical_specialty ,Psychometrics ,medicine.medical_treatment ,Health-related quality of life ,Nomological network ,Home Care Services, Hospital-Based ,Respiratory failure ,Diseases of the respiratory system ,Cronbach's alpha ,Quality of life ,Germany ,Surveys and Questionnaires ,Validation ,medicine ,Outpatient clinic ,Humans ,Medical history ,Translations ,Lebanon ,Aged ,Mechanical ventilation ,RC705-779 ,business.industry ,Research ,Reproducibility of Results ,social sciences ,Middle Aged ,Respiration, Artificial ,Exploratory factor analysis ,Home mechanical ventilation ,Physical therapy ,Quality of Life ,population characteristics ,Female ,business ,Respiratory Insufficiency ,geographic locations - Abstract
Background/objectives Assessment of Health-Related Quality of Life (HRQL) in patients with chronic respiratory insufficiency requiring Home Mechanical Ventilation (HMV) requires a valid measurement tool. The Severe Respiratory Insufficiency (SRI) questionnaire, originally developed in German, has been translated into different languages and tested in different contexts, but has so far not been in use in Arabic-speaking populations. The objective of this study is to validate the Arabic version of the SRI questionnaire in a sample of Arabic-speaking patients from Lebanon. Methods Following forward/backward translations, the finalized Arabic version was administered to 149 patients (53 males–96 females, age 69.80 ± 10 years) receiving HMV. Patients were recruited from outpatient clinics and visited at home. The Arabic SRI and the 36-Item Short-Form Health Survey (SF-36) were administered, in addition to questions on sociodemographics and medical history. Exploratory Factor Analysis (EFA) was used to explore dimensionality; internal consistency reliability of the unidimensional scale and its subscales was assessed using Cronbach’s alpha. External nomological validity was examined by assessing the correlation between the SRI and SF-36 scores. Results The 49-item Arabic SRI scale showed a high internal consistency reliability (Cronbach alpha for the total scale was 0.897 and ranged between 0.73 and 0.87 for all subscales). Correlations between the SF-36-Mental Health Component MHC and SF-36-Physical Health Component with SRI-Summary Scale were 0.57 and 0.66, respectively, with higher correlations observed between the SF-36 and specific sub-scales such as the Physical Functioning and the Social Functioning subscales [r = 0.81 and r = 0.74 (P Conclusion and recommendations The Arabic SRI is a reliable and valid tool for assessing HRQL in patients with chronic respiratory insufficiency receiving home mechanical ventilation.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.